CA1283604C - Dehydrated liposomes - Google Patents
Dehydrated liposomesInfo
- Publication number
- CA1283604C CA1283604C CA000615683A CA615683A CA1283604C CA 1283604 C CA1283604 C CA 1283604C CA 000615683 A CA000615683 A CA 000615683A CA 615683 A CA615683 A CA 615683A CA 1283604 C CA1283604 C CA 1283604C
- Authority
- CA
- Canada
- Prior art keywords
- preparation
- liposomes
- water
- vesicles
- lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
- A61K9/1278—Post-loading, e.g. by ion or pH gradient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
ABSTRACT
Dehydrated liposomes are prepared from a liposome preparation com-posed of liposomes which have multiple lipid layers and removing water from the preparation without prior freezing of the preparation, the water being removed to an end point which results in sufficient water being left in the preparation so that the integrity of a substantial portion of the multiple lipid layers is retained upon rehydration. The dehydrated liposomes may contain a protective sugar. The liposomes are useful in that they can be loaded for example with drugs to provide pharmaceutical preparations.
Dehydrated liposomes are prepared from a liposome preparation com-posed of liposomes which have multiple lipid layers and removing water from the preparation without prior freezing of the preparation, the water being removed to an end point which results in sufficient water being left in the preparation so that the integrity of a substantial portion of the multiple lipid layers is retained upon rehydration. The dehydrated liposomes may contain a protective sugar. The liposomes are useful in that they can be loaded for example with drugs to provide pharmaceutical preparations.
Description
--I--DEHYDRATED LIPOSONES
BACKGROUND OF TH~ INVENTION
1. Field of the Invention ; This invention relates to liposomes and in particular to dehydrated liposomes which can be stored for extended periods of time and then rehydrated when and where they are to be used.
BACKGROUND OF TH~ INVENTION
1. Field of the Invention ; This invention relates to liposomes and in particular to dehydrated liposomes which can be stored for extended periods of time and then rehydrated when and where they are to be used.
2. Description of the Prior Art As is well known in the art, liposomes are closed vesicles having at least one lipid bilayer membrane surrounding an aqueous core. One of the primary uses for liposomes is as carriers for a variety of materials, such as, drugs9 cosmetics, diagnostic reagents, bioactive compounds, and the like.
In connection with each of these uses, it is important to be able to store liposomes for long periods of time without substantial leakage from the liposomes of the selected materials ; they are carrying. More particularly, so as to be useful in commercial settings, liposome preparations must have long enough shelf-lives to allow them to be easily manufactured, shipped, and stored by intermediate and ultimate users under a variety of temperature conditions.
With particular regard to the drug industry, it is also important to be able to provide drug manufacturers with unloaded liposomes whlch the manufacturers can subsequently load in their own plants with their own drugs. Such a two step or two factory approach (i.e., manufacturing unloaded liposomes in a first plant and then filling them in a second plant) would allow drug manufacturers to purchase a defined commodity, i.e., unloaded liposomes, from suppliers and then use that commodity as an off the-shelf component of their final product.
As drug manufacturers currently operate their businesses, they strongly prefer to buy defined commodities from suppliers and ~ 33~
then assemble the final product in their own plants. In this way, they can personally control the quality of the flnished products.
Usage of liposome technology by the drug industry would be greatly - enhanced if liposomes could also be provided to manufacturers as a defined commodity.
To date, liposome preparations have generally had relatively short shelf-lives. Moreover, there has been no known way to prepare liposomes at one point in time and then fill them with selected materials at a much later point in time. The present invention makes up for these existing shortcomings in the current state of the art.
SUMMARY OF TH~ INVENTION
In v~ew of the above state of the art, it is an object of the present invention to provide liposome preparations which can be stored for extended p~riods of time without substantial leakage from the liposomes of internally encapsulated materials.
It is a further object of the present invention to provide liposome preparations which can be dehydrated, stored for extended periods of time while dehydrated, and then rehydrated when and where they are to be used, without losing a substantlal portion of their contents during the dehydration, storage and rehydration processes.
It is an additional object of the present invention to provide liposome preparations which can be dehydrated, stored for extended periods of time while dehydrated, rehydrated, and then filled with selected materials.
To achieve these and other objects, the invention, in accordance with one of its aspects, provides liposome preparations which have been dehydrated in the presence of one or more protective sugars. In certain preferred embodiments of the invention, the liposomes are dehydrated with the one or more sugars being present at both the inside and outside surfaces of the liposome membranes. In other preferred embodiments, the sugars are selected from the group consisting of trehalose, maltoseJ lactose, sucrose, glucose, and dextran, with the most ~ 83604 .:
preferred sugars from a performance point of view being trehalose and sucrose.
The dehydration ls done under vacuum and can take place either with or without prior freezing of the liposome preparation.
5When done without prior freezing, use of the protective sugars can be omitted when (1) the liposomes being dehydrated are of the type which have multiple lipid layers, and (2) the dehydration is done to an end point where there is sufficient water left in the preparation so that a substantial portion of the 10membranes retain their integrity upon rehydrationO Preferably, at least about 2%, and most preferably between about 2% and about 5%, of the original water in the preparation prior to dehydration ; should remain in the preparation at the end of the dehydration process. In terms of moles of water per mole of lipid in the 15dehydrated preparation, this corresponds to a water level of preferably at least about 12 moles water/mole lipid, and most preferably between about 12 and about 35 moles water/mole lipid, in the dehydrated preparation.
In accordance with other aspects of the invention, delayed 20loading of preformed liposomes is achieved by creating a concentration gradient across the liposome membranes of one or more charged species which, under suitable conditions, are capable of passing across those membranes. This concentration gradient is ; used to load selected charged materials, e.g., drugs, into the liposomes through the creation of a transmembrane potential.
It has been found that liposomes having a concentration `gradient across their membranes can be dehydrated in the presence of one or more sugars, as described above and in more detail below, stored in their dehydrated condition, subse~uently rehydrated, and the concentration gradient then used to create a transmembrane potential which will load charged materials into the liposomes. Alternatively, the concentration gradient can be created after the liposomes have been dehydrated, stored, and rehydrated. Also, if the dehydration is done without prior freezing of the liposomes and under the conditions described above, the use of protective sugars may be omitted.
283~
The attainment of the foregoing and other objects and advantages of the present invention is described fully below in connection with the description of the preferred embodiments of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the retention of 22Na+ by dehydrat-ed/rehydrated vesicles as a function of trehalose concentration.
Large unilamellar vesicles were dried without prior freezing (open circles), or after freezing in liquid nitrogen ~open squares).
Figure 2 shows freeza-fracture electron micrographs of vesicles before (Fig. 2a -- Control) and after (Fig. 2b -- Freeze Dried) dehydration/rehydration with prior freezing. Egg phosphatidylcholine vesicles were prepared by extruding large multilamellar vesicles through a 100 nm polycarbonate filter. The vesicles were dehydrated in the presence of 250 mM trehalose.
Figure 3 shows freeze-fracture electron micrographs of egg phosphatidylcholine vesicles before and after dehydrationO The ~ vesicles were prepared by extruding large multilamellar vesicles i through a 100 nm polycarbonate filter. Fig. 3a shows the vesicles prior to dehydration. Fig. 3b shows the much larger structures obtained by dehydrating and then rehydrating the vesicles without ~ the use of trehalose. Fig. 3c and Fig. 3d show the vesicles after - dehydration and rehydration in the presence of 50 mM and 125 mMtrehalose, respectively. The diameter of the large liposome in Fig. 3b is approximately 900 nm and the arrows in the upper right hand corners of the figures indicate the direction of shadowing.
Figure 4 shows the retention of 3H-inulin as a function of trehalose concentration. Large unilamellar vesicles containing entrapped 3H-inulin were dried under high vacuum without prior freezing.
Figure 5 shows the influence of sodium chloride concentration on the amount of 22Na+ retained by dehydrated/rehydrated vesicles.
The vesicles were dried in the presence of 250 mM trehalose under high vacuum for 24 hours.
Figure 6 shows the transmembrane potentials generated by a pH
gradient for control vesicles (squares) and dehydrated/rehydrated ~2~36~
vesicles (circles). Vesicles with a pre-existing proton gradient were maintained at 4C for 24 hours (control) or dehydrated in the-presence of 250 mM trehalose under high vacuum for the same period of time. The potential observed in the vesicles upon rehydration was determined in the absence of CCCP (open circles and squares), or with 20 uM CCCP present (solid circles and squares), using the probe 3H-tetraphenylphosphonium bromide. The transmembrane potentials observed in vesicles without a pH gradient in the presence and absence of CCCP is shown by the solid and open triangles, respectively.
Figure 7 shows the transmembrane potentials generated by a Na /~ chemical gradient for control veslcles (squares) and ~ dehydrated/rehydrated vesicles (circles). Vesicles with a ; pre-existing Na /K gradient were maintained at 4C for 24 hours (control) or dehydrated in the presence of 250 mM trehalose under high vacuum for the same period of time. The potential observed in the vesicles upon rehydration was determined in the absence of valinomycln (solid circles and squares), or with 0.5 ug/umole phospholipid valinomycin present (open circles and squares), using the probe H-tetraphenylphosphonium bromide. The transmembrane potentials observed in vesicles having potassium glutamate on both sides of the membrane in the presence and absence of valinomycin is shown by the open and solid triangles, respectively.
Figure ~ illustrates the use of a transmembrane potential to load adriamycin into previously dried vesicles. Vesicles with a pre-existing Na / ~ gradient were dehydrated for 24 hours in the presence of 25~ ~M trehalose. Following rehydration the ability of the vesicles to accumulate adriamycin in the presence (open circles), or absence (solid circles) of valinomycin (0.5 ug/umole phospholipid) was measured. Control vesicles maintained at 4C
for the same period were also tested in the presence (open squares) or absence (solid squares) of valinomycin.
Figure 9 shows the retention of inulin in freeze and thaw multilamellar vesicles (FATMLVs) and stable plurilamellar vesicles (SPLVs) as a function of the percentage of the original water remaining in the preparation at the end of the dehydration -6~
process. The liposomes were dehydrated in the absence of protec-tive sugars under reduced pressure.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
As described above, the present invention relates to lipo-somes which can be subjected to long-term storage without sub-stantial loss of their internal contents. The liposomes are stored in a dehydrated state, and the dehydration is performed in the presence of one or more protective sugars. Alternatively, if the liposomes being dehydrated are of the type which have multiple lipid layers and if the dehydration is performed without prior freezing and to an end point where there is sufficient water left in the preparation so that a substantial portion of the membranes retain their integrity upon rehydration, the use of a protective `; sugar may be omitted.
The liposomes which are to be dehydrated can have a variety of compositions and internal contents, and can be in the form of multilamellar, unilamellar, or other types of liposomes or, more generally, lipid-containing particles, now known or later devel-oped. For example, the lipid-contalning particles can be in the form of steroidal liposomes, stable plurilamellar liposomes (SPLVs), monophasic vesicles (MPVs), or lipid matrix carriers (LMCs) of the types disclosed in commonly assigned U.S. Patents Nos. 4,522,803; 4,588,578; and 4,610,868, issued ~une 11, 1985, May 13, 1986 and September 9, 1986 respectively and Canadian Pat-; 25 ent Application No. 491,321, or can be in the form of freeze and thaw multilamellar vesicles (FATMLVs) of the type described in copending and commonly assigned Canadian Patent Application No.
520,029 and entitled "Multilamellar Liposomes Having Improved Trapping Efficiencies".
The liposomes can be prepared by any of the techniques now known or subsequently developed for preparing liposomes. For ex-ample, the liposomes can be formed by the conventional technique for preparing multilamellar liposomes (MLVs3, that is, by de-; positing one or more selected lipids on the inside walls of a -7- ~283~
suitable vessel by dissolving the lipids in chloroform and then evaporating the chloroform, adding the aqueous solution which is to be encapsulated to the vessel, allowing the aqueous solution to hydrate the lipid, and swirling or vortexing the resulting lipid suspension to produce the desired liposomes.
Alternatively, techniques used for producing large unilamel-lar liposomes (LUVs), such as, reverse-phase evaporation, infusion procedures, and detergent dilution, can be used to produce the liposomes. A review of these and other methods for producing liposomes can be found in the text Liposomes, Marc J. Ostro, ed., Marcel Dekker, Inc., New York, 1983, Chapter 1. See also Szoka, Jr., et al., (1980) Ann. Rev. Biophys. Bioengr., 9:467. A partic-ularly preferred method for preparing LUVs is described in com-monly assigned and copending Canadian Patent Application No.
483,485 and entitled "Extrusion Technique for Porducing Unilamel-lar Vesicles".
As other alternatives, the liposomes can be produced in ac-cordance with the procedures described in U.S. Patents Nos.
4,522,803 and 4,588,578 and Canadian Patent Application No. 491, 321, referred to above, or in accordance with the freeze and thaw procedures described in Canadian Patent Application No. 520, 029, also referred to above. Also~ rather than using liposomes per se, other lipid-containing particles, such as those described ; in U.S. Patent No. 4,610,868, referred to above, can be used in the practice of the present invention. Furthermore, if desired, the liposomes or lipid-containing particles which are to be de-hydrated can be given a more uniform size distribution by subject-ing them to the process of commonly assigned and copending Cana-dian Patent Application No. 483,485.
~8~
The liposomes are preferably dehydrated using standard Ereeze-drying equipment or equivalent apparatus, that is, they are preferably dehydrated under reduced pressure. If desired, the liposomes and their surrounding medium can be frozen in liquid nitrogen before being dehydrated~ Alternatively, and quite sur-prisingly, the liposomes can also be dehydrated without prior freezing, by simply being placed under reduced pressure.
Dehydration without prior freezing takes longer than dehydration with prior freezing, but the overall process is gentler without the freezing step, and thus there is in general less damage to the liposomes and a corresponding smaller loss of the internal contents of the liposomes. For example, dehydration without prior freezing at room temperature and at a reduced pressure provided by a vacuum pump capable of producing a pressure on the order of 1 mm ~ 15 of mercury can take between approximately 24 and 36 hours 9 while-I dehydration with prior freezing under the same condltions can take between approximately 12 and 24 hours.
So that the liposomes will survive the dehydration process without losing a substantial portion of their internal contents, it is important that one or more protective sugars be available to interact with the liposome membranes and keep them intact as the water in the system is removed. A variety of sugars can be used, including such sugars as trehalose, maltose, sucrose, glucose, lactose, and dextran. In general, disaccharide sugars have been found to work better than monosaccharide sugars, with the disaccharide sugars trehalose and sucrose being most effective.
Other more complicated sugars can also be used. For example, aminoglycosides, including streptomycin and dihydrostreptomycin, have been found to protect liposomes during dehydration.
The one or more sugars are included as part of either the internal or external media of the liposomes. Most preferably, the sugars are included in both the internal and external media so that they can interact with both the inside and outside surfaces ; of the liposomes' membranes. Inclusion in the internal medium is accomplished by adding the sugar or sugars to the solute which the liposomes are to encapsulate. Since in most cases this solute ~LZ83~4 also forms the bathing medium for the f~nished liposomes, inclusion of the sugars in the solute also makes them part of the external medium. Of course, if an external medium o~her than the original solute is used, e.g., to create a transmembrane potential (see below), the new external medium should also include one or more of the protective sugars.
The amount of sugar to be used depends on the type of sugar used and the characteristics of the liposomes to be protected. As illustrated by Examples 1-5, below, persons skilled in the art can test various sugar types and concentrations to determine which combination works best for a particular liposome preparation. In general, sugar concentrations on the order of 100 mM and above have been found necessary to achieve the highest levels of protection. In terms of moles of membrane phospholipid, millimolar levels on the order of 100 mM correspond to approximately 5 moles of sugar per mole of phospholipid.
In the case of dehydration without prior freezing, if the liposomes being dehydrated are of the type which have multiple lipid layers and if the dehydration is carried out to an end point where there is sufficient water left in the preparation so that a substantial portion of the membranes retain their integrity upon rehydration, the use of one or more protective sugars may be omitted. As discussed above, it has been found preferable if the preparation contains at the end of the dehydration process at least about 2%, and most preferably between about 2% and about 5~, of the original water present in the preparation prior to dehydration.
Once the liposomes have been dehydrated, they can be stored for extended periods of time until they are to be used. The appropriate temperature for storage will depend on the make up of the liposomes and the temperature sensitivity of the encapsulated materials. For example, as is well known in the art, various drug preparations are heat labile, and thus dehydrated liposomes containing such drugs should be stored under refrigerated conditions so that the drugs do not lose their potency. Also, for -~28~ 04 such drugs, the dehydration process is preferably carried oue at reduced eemperatures 9 rather than at room temperature.
When the dehydrated liposomes are eO be used, rehydraeion is accomplished by simply adding an aqueous solution, e.g., distilled water, to the liposomes and allowing them to rehydrate. The liposomes can be resuspended into the aqueous solu lon by gentle swirling of ehe solution. The rehydration can be performed at room temperature or at other temperatures appropriate to the composition of the liposomes and their internal contents.
As discussed above, for certain applications, e.g., drug administration, it is desirable to be able to separate the process of loading liposomes from the process of preparing them. This can be accomplished by creatlng a transmembrane potential across the membranes of preformed liposomes and using that transme~brane po-tential eo load charged materials, e.g., charged drugs, into the liposomes. The transmembrane potential is generated by creating a conceneration gradient for one or more charged species (e.g., K
and/or H ) across the liposome membranes. The concentration gradient ls created by producing liposomes having different internal and external media, l.e., internal and external media having different concentrations of the one or more charged species.
Specifically, llposomes are prepared which encapsulate a first medium having a first concentration of the one or more ~5 charged species. For a typical liposome preparation technique (see discus~ion above), this flrst medium will surround the liposomes as they are for~ed, and thus the liposomes' orlginal external medium will have the same co~position as the first me-dium. To create the concentration gradlent, ehe original external medium is replaced by a new external medium having a different concentration of ehe one or more charged species. The replacement of the external medium can be accomplished by various eechniques, such as, by passing the liposome preparation through a gel fi~-tration column, e.g., a Sephadex column, whlch has been equillbrated with the new medium, or by centrifugation, dialysis, or related techniques.
* Trade Mark Depending upon the permeability of the liposome membranes, the full transmembrane potential corresponding to the concentration gradient will either form spontaneously or a permeability enhancing agent, e.g., an ionophore, such as, valinomycin, may have to be added to the bathing medium. (Note that, if desired, the permeability enhancing agent can be removed from the preparation after loading has been completed using chromatography or other techniques). In either case, a transmem-brane potential having a magnitude defined by the Nernst equation will appear across the liposomes' membranes. This transmembrane potential will cause charged materials, e.g., charged drugs, to be loaded into the liposomes. Specifically, the transmembrane potential will ~ause those materials whose charge is opposite to ;the internal potential of the liposomes (outside ground~ to accumulate within the liposomes. Thus, by adding to the external medium the material one wants to load and by choosing the concen-tration gradient and thus the transmembrane potential to have the appropriate orientation, loading of the liposomes can be accomplished as a separate operation from the creation of the liposomes.
; The combination of transmembrane potential loading and liposome dehydration allows for great flexibility in the overall procedure for producing the finished, loaded liposomes. For example, liposomes having the same internal and external media, i.e., no transmembrane potentials, can be prepared, dehydrated, ~;stored, rehydrated, and then the external medium can be replaced with a new medium having a composition which will generate transmembrane potentials, and the transmembrane potentials used to load the liposomes. Alternatively, liposomes having internal and external media which will produce transmembrane potentials can be prepared, dehydrated, stored, rehydrated, and then loaded using the transmembrane potentials.
In either case, when in their dehydrated state, the unloaded liposomes can be stored, shipped and otherwise easily handled. In particular, the dehydrated, unloaded liposomes are exactly the type of defined commodity which drug manufacturers prefer to -12- ~283G~
purchase and thus satisfy the long felt need for a liposome pro-duct of this type (see discussion above).
A particularly important application of these transmembrane potential loading and/or liposome dehydration procedures is in the area of the administration of antineoplastic agents, such as, ad-riamycin (see Examples 1 and 6, below). A further discussion of these applications can be found in copending and commonly assigned Canadian Patent Application No. 400,005 and entitled "Encapsulation of Antineoplastic Agents in Liposomes".
Without intending to limit it in any manner, the present in-vention will be more fully described by the following examples.
The materials and methods which are common to the various examples are as follows.
Materials and Methods Materials Egg phosphatidylcholine (EPC) was isolated employing standard procedures (see~ for example, Singleton, et al., (19~5) Journal of the American Oil Chemical Society, 42:53) and was more than 99%
pure as determined by TLC. Trehalose, maltose, sucrose and glu-cose were obtained from the Sigma Chemical Company (St. Louis,Mo.), while lactose was purchased from Fisher Scientific Company 22Na+ 3H-inulin, 3H-tetraphenylphospho bromide and 3H-H20 were obtained from New England Nuclear (Lachine, Quebec). Adriamycin was obtained from Adria Laboratory (Missis-sauga, Ontario).Vesicle Preparation Vesicles were prepared using the extrusion techniques des-cribed in Canadian Patent Application No. 483,485, referred to above. A complete description of the techniques used appears in that application. Vesicles prepared by these techniques will be referred to herein as ETVs, i.e. Extrusion Technique _esicles.
Briefly, 80 umoles of egg phosphatidylcholine were hydrated with 2 ml of 150 mM NaCl, 20 mM HEPES (pH 7.4) containing the
In connection with each of these uses, it is important to be able to store liposomes for long periods of time without substantial leakage from the liposomes of the selected materials ; they are carrying. More particularly, so as to be useful in commercial settings, liposome preparations must have long enough shelf-lives to allow them to be easily manufactured, shipped, and stored by intermediate and ultimate users under a variety of temperature conditions.
With particular regard to the drug industry, it is also important to be able to provide drug manufacturers with unloaded liposomes whlch the manufacturers can subsequently load in their own plants with their own drugs. Such a two step or two factory approach (i.e., manufacturing unloaded liposomes in a first plant and then filling them in a second plant) would allow drug manufacturers to purchase a defined commodity, i.e., unloaded liposomes, from suppliers and then use that commodity as an off the-shelf component of their final product.
As drug manufacturers currently operate their businesses, they strongly prefer to buy defined commodities from suppliers and ~ 33~
then assemble the final product in their own plants. In this way, they can personally control the quality of the flnished products.
Usage of liposome technology by the drug industry would be greatly - enhanced if liposomes could also be provided to manufacturers as a defined commodity.
To date, liposome preparations have generally had relatively short shelf-lives. Moreover, there has been no known way to prepare liposomes at one point in time and then fill them with selected materials at a much later point in time. The present invention makes up for these existing shortcomings in the current state of the art.
SUMMARY OF TH~ INVENTION
In v~ew of the above state of the art, it is an object of the present invention to provide liposome preparations which can be stored for extended p~riods of time without substantial leakage from the liposomes of internally encapsulated materials.
It is a further object of the present invention to provide liposome preparations which can be dehydrated, stored for extended periods of time while dehydrated, and then rehydrated when and where they are to be used, without losing a substantlal portion of their contents during the dehydration, storage and rehydration processes.
It is an additional object of the present invention to provide liposome preparations which can be dehydrated, stored for extended periods of time while dehydrated, rehydrated, and then filled with selected materials.
To achieve these and other objects, the invention, in accordance with one of its aspects, provides liposome preparations which have been dehydrated in the presence of one or more protective sugars. In certain preferred embodiments of the invention, the liposomes are dehydrated with the one or more sugars being present at both the inside and outside surfaces of the liposome membranes. In other preferred embodiments, the sugars are selected from the group consisting of trehalose, maltoseJ lactose, sucrose, glucose, and dextran, with the most ~ 83604 .:
preferred sugars from a performance point of view being trehalose and sucrose.
The dehydration ls done under vacuum and can take place either with or without prior freezing of the liposome preparation.
5When done without prior freezing, use of the protective sugars can be omitted when (1) the liposomes being dehydrated are of the type which have multiple lipid layers, and (2) the dehydration is done to an end point where there is sufficient water left in the preparation so that a substantial portion of the 10membranes retain their integrity upon rehydrationO Preferably, at least about 2%, and most preferably between about 2% and about 5%, of the original water in the preparation prior to dehydration ; should remain in the preparation at the end of the dehydration process. In terms of moles of water per mole of lipid in the 15dehydrated preparation, this corresponds to a water level of preferably at least about 12 moles water/mole lipid, and most preferably between about 12 and about 35 moles water/mole lipid, in the dehydrated preparation.
In accordance with other aspects of the invention, delayed 20loading of preformed liposomes is achieved by creating a concentration gradient across the liposome membranes of one or more charged species which, under suitable conditions, are capable of passing across those membranes. This concentration gradient is ; used to load selected charged materials, e.g., drugs, into the liposomes through the creation of a transmembrane potential.
It has been found that liposomes having a concentration `gradient across their membranes can be dehydrated in the presence of one or more sugars, as described above and in more detail below, stored in their dehydrated condition, subse~uently rehydrated, and the concentration gradient then used to create a transmembrane potential which will load charged materials into the liposomes. Alternatively, the concentration gradient can be created after the liposomes have been dehydrated, stored, and rehydrated. Also, if the dehydration is done without prior freezing of the liposomes and under the conditions described above, the use of protective sugars may be omitted.
283~
The attainment of the foregoing and other objects and advantages of the present invention is described fully below in connection with the description of the preferred embodiments of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows the retention of 22Na+ by dehydrat-ed/rehydrated vesicles as a function of trehalose concentration.
Large unilamellar vesicles were dried without prior freezing (open circles), or after freezing in liquid nitrogen ~open squares).
Figure 2 shows freeza-fracture electron micrographs of vesicles before (Fig. 2a -- Control) and after (Fig. 2b -- Freeze Dried) dehydration/rehydration with prior freezing. Egg phosphatidylcholine vesicles were prepared by extruding large multilamellar vesicles through a 100 nm polycarbonate filter. The vesicles were dehydrated in the presence of 250 mM trehalose.
Figure 3 shows freeze-fracture electron micrographs of egg phosphatidylcholine vesicles before and after dehydrationO The ~ vesicles were prepared by extruding large multilamellar vesicles i through a 100 nm polycarbonate filter. Fig. 3a shows the vesicles prior to dehydration. Fig. 3b shows the much larger structures obtained by dehydrating and then rehydrating the vesicles without ~ the use of trehalose. Fig. 3c and Fig. 3d show the vesicles after - dehydration and rehydration in the presence of 50 mM and 125 mMtrehalose, respectively. The diameter of the large liposome in Fig. 3b is approximately 900 nm and the arrows in the upper right hand corners of the figures indicate the direction of shadowing.
Figure 4 shows the retention of 3H-inulin as a function of trehalose concentration. Large unilamellar vesicles containing entrapped 3H-inulin were dried under high vacuum without prior freezing.
Figure 5 shows the influence of sodium chloride concentration on the amount of 22Na+ retained by dehydrated/rehydrated vesicles.
The vesicles were dried in the presence of 250 mM trehalose under high vacuum for 24 hours.
Figure 6 shows the transmembrane potentials generated by a pH
gradient for control vesicles (squares) and dehydrated/rehydrated ~2~36~
vesicles (circles). Vesicles with a pre-existing proton gradient were maintained at 4C for 24 hours (control) or dehydrated in the-presence of 250 mM trehalose under high vacuum for the same period of time. The potential observed in the vesicles upon rehydration was determined in the absence of CCCP (open circles and squares), or with 20 uM CCCP present (solid circles and squares), using the probe 3H-tetraphenylphosphonium bromide. The transmembrane potentials observed in vesicles without a pH gradient in the presence and absence of CCCP is shown by the solid and open triangles, respectively.
Figure 7 shows the transmembrane potentials generated by a Na /~ chemical gradient for control veslcles (squares) and ~ dehydrated/rehydrated vesicles (circles). Vesicles with a ; pre-existing Na /K gradient were maintained at 4C for 24 hours (control) or dehydrated in the presence of 250 mM trehalose under high vacuum for the same period of time. The potential observed in the vesicles upon rehydration was determined in the absence of valinomycln (solid circles and squares), or with 0.5 ug/umole phospholipid valinomycin present (open circles and squares), using the probe H-tetraphenylphosphonium bromide. The transmembrane potentials observed in vesicles having potassium glutamate on both sides of the membrane in the presence and absence of valinomycin is shown by the open and solid triangles, respectively.
Figure ~ illustrates the use of a transmembrane potential to load adriamycin into previously dried vesicles. Vesicles with a pre-existing Na / ~ gradient were dehydrated for 24 hours in the presence of 25~ ~M trehalose. Following rehydration the ability of the vesicles to accumulate adriamycin in the presence (open circles), or absence (solid circles) of valinomycin (0.5 ug/umole phospholipid) was measured. Control vesicles maintained at 4C
for the same period were also tested in the presence (open squares) or absence (solid squares) of valinomycin.
Figure 9 shows the retention of inulin in freeze and thaw multilamellar vesicles (FATMLVs) and stable plurilamellar vesicles (SPLVs) as a function of the percentage of the original water remaining in the preparation at the end of the dehydration -6~
process. The liposomes were dehydrated in the absence of protec-tive sugars under reduced pressure.
DESCRIPTION OF THE PREFERRED EMBODIMENTS
As described above, the present invention relates to lipo-somes which can be subjected to long-term storage without sub-stantial loss of their internal contents. The liposomes are stored in a dehydrated state, and the dehydration is performed in the presence of one or more protective sugars. Alternatively, if the liposomes being dehydrated are of the type which have multiple lipid layers and if the dehydration is performed without prior freezing and to an end point where there is sufficient water left in the preparation so that a substantial portion of the membranes retain their integrity upon rehydration, the use of a protective `; sugar may be omitted.
The liposomes which are to be dehydrated can have a variety of compositions and internal contents, and can be in the form of multilamellar, unilamellar, or other types of liposomes or, more generally, lipid-containing particles, now known or later devel-oped. For example, the lipid-contalning particles can be in the form of steroidal liposomes, stable plurilamellar liposomes (SPLVs), monophasic vesicles (MPVs), or lipid matrix carriers (LMCs) of the types disclosed in commonly assigned U.S. Patents Nos. 4,522,803; 4,588,578; and 4,610,868, issued ~une 11, 1985, May 13, 1986 and September 9, 1986 respectively and Canadian Pat-; 25 ent Application No. 491,321, or can be in the form of freeze and thaw multilamellar vesicles (FATMLVs) of the type described in copending and commonly assigned Canadian Patent Application No.
520,029 and entitled "Multilamellar Liposomes Having Improved Trapping Efficiencies".
The liposomes can be prepared by any of the techniques now known or subsequently developed for preparing liposomes. For ex-ample, the liposomes can be formed by the conventional technique for preparing multilamellar liposomes (MLVs3, that is, by de-; positing one or more selected lipids on the inside walls of a -7- ~283~
suitable vessel by dissolving the lipids in chloroform and then evaporating the chloroform, adding the aqueous solution which is to be encapsulated to the vessel, allowing the aqueous solution to hydrate the lipid, and swirling or vortexing the resulting lipid suspension to produce the desired liposomes.
Alternatively, techniques used for producing large unilamel-lar liposomes (LUVs), such as, reverse-phase evaporation, infusion procedures, and detergent dilution, can be used to produce the liposomes. A review of these and other methods for producing liposomes can be found in the text Liposomes, Marc J. Ostro, ed., Marcel Dekker, Inc., New York, 1983, Chapter 1. See also Szoka, Jr., et al., (1980) Ann. Rev. Biophys. Bioengr., 9:467. A partic-ularly preferred method for preparing LUVs is described in com-monly assigned and copending Canadian Patent Application No.
483,485 and entitled "Extrusion Technique for Porducing Unilamel-lar Vesicles".
As other alternatives, the liposomes can be produced in ac-cordance with the procedures described in U.S. Patents Nos.
4,522,803 and 4,588,578 and Canadian Patent Application No. 491, 321, referred to above, or in accordance with the freeze and thaw procedures described in Canadian Patent Application No. 520, 029, also referred to above. Also~ rather than using liposomes per se, other lipid-containing particles, such as those described ; in U.S. Patent No. 4,610,868, referred to above, can be used in the practice of the present invention. Furthermore, if desired, the liposomes or lipid-containing particles which are to be de-hydrated can be given a more uniform size distribution by subject-ing them to the process of commonly assigned and copending Cana-dian Patent Application No. 483,485.
~8~
The liposomes are preferably dehydrated using standard Ereeze-drying equipment or equivalent apparatus, that is, they are preferably dehydrated under reduced pressure. If desired, the liposomes and their surrounding medium can be frozen in liquid nitrogen before being dehydrated~ Alternatively, and quite sur-prisingly, the liposomes can also be dehydrated without prior freezing, by simply being placed under reduced pressure.
Dehydration without prior freezing takes longer than dehydration with prior freezing, but the overall process is gentler without the freezing step, and thus there is in general less damage to the liposomes and a corresponding smaller loss of the internal contents of the liposomes. For example, dehydration without prior freezing at room temperature and at a reduced pressure provided by a vacuum pump capable of producing a pressure on the order of 1 mm ~ 15 of mercury can take between approximately 24 and 36 hours 9 while-I dehydration with prior freezing under the same condltions can take between approximately 12 and 24 hours.
So that the liposomes will survive the dehydration process without losing a substantial portion of their internal contents, it is important that one or more protective sugars be available to interact with the liposome membranes and keep them intact as the water in the system is removed. A variety of sugars can be used, including such sugars as trehalose, maltose, sucrose, glucose, lactose, and dextran. In general, disaccharide sugars have been found to work better than monosaccharide sugars, with the disaccharide sugars trehalose and sucrose being most effective.
Other more complicated sugars can also be used. For example, aminoglycosides, including streptomycin and dihydrostreptomycin, have been found to protect liposomes during dehydration.
The one or more sugars are included as part of either the internal or external media of the liposomes. Most preferably, the sugars are included in both the internal and external media so that they can interact with both the inside and outside surfaces ; of the liposomes' membranes. Inclusion in the internal medium is accomplished by adding the sugar or sugars to the solute which the liposomes are to encapsulate. Since in most cases this solute ~LZ83~4 also forms the bathing medium for the f~nished liposomes, inclusion of the sugars in the solute also makes them part of the external medium. Of course, if an external medium o~her than the original solute is used, e.g., to create a transmembrane potential (see below), the new external medium should also include one or more of the protective sugars.
The amount of sugar to be used depends on the type of sugar used and the characteristics of the liposomes to be protected. As illustrated by Examples 1-5, below, persons skilled in the art can test various sugar types and concentrations to determine which combination works best for a particular liposome preparation. In general, sugar concentrations on the order of 100 mM and above have been found necessary to achieve the highest levels of protection. In terms of moles of membrane phospholipid, millimolar levels on the order of 100 mM correspond to approximately 5 moles of sugar per mole of phospholipid.
In the case of dehydration without prior freezing, if the liposomes being dehydrated are of the type which have multiple lipid layers and if the dehydration is carried out to an end point where there is sufficient water left in the preparation so that a substantial portion of the membranes retain their integrity upon rehydration, the use of one or more protective sugars may be omitted. As discussed above, it has been found preferable if the preparation contains at the end of the dehydration process at least about 2%, and most preferably between about 2% and about 5~, of the original water present in the preparation prior to dehydration.
Once the liposomes have been dehydrated, they can be stored for extended periods of time until they are to be used. The appropriate temperature for storage will depend on the make up of the liposomes and the temperature sensitivity of the encapsulated materials. For example, as is well known in the art, various drug preparations are heat labile, and thus dehydrated liposomes containing such drugs should be stored under refrigerated conditions so that the drugs do not lose their potency. Also, for -~28~ 04 such drugs, the dehydration process is preferably carried oue at reduced eemperatures 9 rather than at room temperature.
When the dehydrated liposomes are eO be used, rehydraeion is accomplished by simply adding an aqueous solution, e.g., distilled water, to the liposomes and allowing them to rehydrate. The liposomes can be resuspended into the aqueous solu lon by gentle swirling of ehe solution. The rehydration can be performed at room temperature or at other temperatures appropriate to the composition of the liposomes and their internal contents.
As discussed above, for certain applications, e.g., drug administration, it is desirable to be able to separate the process of loading liposomes from the process of preparing them. This can be accomplished by creatlng a transmembrane potential across the membranes of preformed liposomes and using that transme~brane po-tential eo load charged materials, e.g., charged drugs, into the liposomes. The transmembrane potential is generated by creating a conceneration gradient for one or more charged species (e.g., K
and/or H ) across the liposome membranes. The concentration gradient ls created by producing liposomes having different internal and external media, l.e., internal and external media having different concentrations of the one or more charged species.
Specifically, llposomes are prepared which encapsulate a first medium having a first concentration of the one or more ~5 charged species. For a typical liposome preparation technique (see discus~ion above), this flrst medium will surround the liposomes as they are for~ed, and thus the liposomes' orlginal external medium will have the same co~position as the first me-dium. To create the concentration gradlent, ehe original external medium is replaced by a new external medium having a different concentration of ehe one or more charged species. The replacement of the external medium can be accomplished by various eechniques, such as, by passing the liposome preparation through a gel fi~-tration column, e.g., a Sephadex column, whlch has been equillbrated with the new medium, or by centrifugation, dialysis, or related techniques.
* Trade Mark Depending upon the permeability of the liposome membranes, the full transmembrane potential corresponding to the concentration gradient will either form spontaneously or a permeability enhancing agent, e.g., an ionophore, such as, valinomycin, may have to be added to the bathing medium. (Note that, if desired, the permeability enhancing agent can be removed from the preparation after loading has been completed using chromatography or other techniques). In either case, a transmem-brane potential having a magnitude defined by the Nernst equation will appear across the liposomes' membranes. This transmembrane potential will cause charged materials, e.g., charged drugs, to be loaded into the liposomes. Specifically, the transmembrane potential will ~ause those materials whose charge is opposite to ;the internal potential of the liposomes (outside ground~ to accumulate within the liposomes. Thus, by adding to the external medium the material one wants to load and by choosing the concen-tration gradient and thus the transmembrane potential to have the appropriate orientation, loading of the liposomes can be accomplished as a separate operation from the creation of the liposomes.
; The combination of transmembrane potential loading and liposome dehydration allows for great flexibility in the overall procedure for producing the finished, loaded liposomes. For example, liposomes having the same internal and external media, i.e., no transmembrane potentials, can be prepared, dehydrated, ~;stored, rehydrated, and then the external medium can be replaced with a new medium having a composition which will generate transmembrane potentials, and the transmembrane potentials used to load the liposomes. Alternatively, liposomes having internal and external media which will produce transmembrane potentials can be prepared, dehydrated, stored, rehydrated, and then loaded using the transmembrane potentials.
In either case, when in their dehydrated state, the unloaded liposomes can be stored, shipped and otherwise easily handled. In particular, the dehydrated, unloaded liposomes are exactly the type of defined commodity which drug manufacturers prefer to -12- ~283G~
purchase and thus satisfy the long felt need for a liposome pro-duct of this type (see discussion above).
A particularly important application of these transmembrane potential loading and/or liposome dehydration procedures is in the area of the administration of antineoplastic agents, such as, ad-riamycin (see Examples 1 and 6, below). A further discussion of these applications can be found in copending and commonly assigned Canadian Patent Application No. 400,005 and entitled "Encapsulation of Antineoplastic Agents in Liposomes".
Without intending to limit it in any manner, the present in-vention will be more fully described by the following examples.
The materials and methods which are common to the various examples are as follows.
Materials and Methods Materials Egg phosphatidylcholine (EPC) was isolated employing standard procedures (see~ for example, Singleton, et al., (19~5) Journal of the American Oil Chemical Society, 42:53) and was more than 99%
pure as determined by TLC. Trehalose, maltose, sucrose and glu-cose were obtained from the Sigma Chemical Company (St. Louis,Mo.), while lactose was purchased from Fisher Scientific Company 22Na+ 3H-inulin, 3H-tetraphenylphospho bromide and 3H-H20 were obtained from New England Nuclear (Lachine, Quebec). Adriamycin was obtained from Adria Laboratory (Missis-sauga, Ontario).Vesicle Preparation Vesicles were prepared using the extrusion techniques des-cribed in Canadian Patent Application No. 483,485, referred to above. A complete description of the techniques used appears in that application. Vesicles prepared by these techniques will be referred to herein as ETVs, i.e. Extrusion Technique _esicles.
Briefly, 80 umoles of egg phosphatidylcholine were hydrated with 2 ml of 150 mM NaCl, 20 mM HEPES (pH 7.4) containing the
3~iO4 ~ indicated concentration of trehalose or other sugars. In those ; cases where the amount of residual water present after dehydraeion ; was determined, 3H-wa~er (30 uCi) was added to the HEPES buf-fer/sugar solution. Na (5 uCi) or H-inulin (5 uCi; specific activity 409 mCi/g) were added to the dry lipid prior to hydration.
The mixture was dispersed by vortexing and then passed ten times through two stacked polycarbonate filters of 100 nm pore size (Nuclepore, Inc., Pleasanton, CA) using a pressure of 250 psi. In those cases where a freeze-thaw procedure was utilized, the vesicles were prepared as above, freeze-thawed once using liquid nitrogen, and then again repeatedly passed through the stacked flleers.
; Unencapsulated 22Na+ or 3H-inulin was removed by passing thevesicles through a column (1.4 x 10 cm) of either Sephadex C-50 (fine) for removal of 22Na or Ultragel AcA 34 for removal of H~inulin. This procedure generally diluted the phospholipid coneent of the sample by approximately S0~ to sive a concentration of about 20 umoles phospholipld per mlllillter.
Sample~ (1 ml) were dried in 10 m~ Kimex tubes at room temperature under high vacuum using a Virtis Freeze Drler ~Cardiner, N.Y.). In some cases, the samples were frozen in ; llquid nitrogen prior to dehydration. In either case, the reducedpressure dehydration process was carried out for approximately 24 hours.
Rehydration Followlng dehydration and storage for perlods ranging from 1 to 7 days, the samples were rehydrated with diseilled water (900 ul) and the vesicles dlspersed by gentle vortexing. The amount of entrapped 2Na , 3H-inulin or adriamycin remainin8 wiehin the vesicles was measured uslng the techniques described below (see 'Assays") after passage of 100 ul aliquots of the vesicle suspension over columns (1 ml) of Sephadex G-50 (fine) or ~ltragel AcA 34, equilibrated with the same solution in which the vesicles were suspended, to remove any untrapped materlal (see Canadian * Trade Mark 1l :28~6~4 Patent Application No. 483,485 for furthe~ details). Since the columns tend to trap a small percentage of the liposomes applied thereto, the values reported oelow for the amounts of encapsulated material retalned after the dehydration/rehydration process are somewhat lower than the levels actually achieved by the procedures of the present inventlon.
Free~e Fracture Electron Microscop~
Samples for freeze-fracture contained 25~ glycerol and were fractured and replicated following the procedures described in Madden, T.D., Hope, M.J. and Cullis, P~R. (1983) Biochemistry 22, 1970-1974, using a Balzers freeze-fracture apparatus. Replicas were visuali~ed on a Phillips 400 electron microscope.
Quasi-Elastic Light Sca~ttering Measurements *
Vesicles were slzed employing a Nicomp 200 Laser Particle Sizer (Nicomp lnstrument, Goleta, CA) operating at 632.8 nm and 5 ;nW.
~ Assays ; Phospholipids were quantified by determination of inorganic phosphorus as described by Chen, et al., (1956) Anal. Chem.
28:1756. Adrlamycin uptake was measured following solubilization of vesicles in 0.5% Triton X-lOQ from its absorbance at 480 nm.
3H-inulin, 3H-H20 and 3H-tetraphenylphosphonium were counted in a Phillips PW 4700 liquid scintillation counter, while 22Na was *
quantlfied by gam~a counting on a Beckman Gamma 800.
Example 1 Dehydration of_Liposomes Usin~the Protective Sugar Trehalose This example illuseraees the ability of ehe sugar ~rehalose eO protect liposomes from substantial loss of their internal contents during dehydraeion and subsequent rehydration.
Experimenes demonstrating high reteneion levels for 22Na , H-inulin, and adriamycin were performed. The results are shown in Figures 1-4 and Table 1.
In particular, egg phosphatidylcholine ETVs were prepared as described above using solute solueions containing 22~a and various concentratlons of trehalose. The ETVs were dehydrated * Trade Mark -15- ~L2836~4 with or without prior freezlng in liquid nitrogen, rehydrated and assayed as described above. The results are shown in Figure 1.
As shown in that figure, the amount of 22Na retainsd in the vesicles after rehydration depends on the trehalose concentration, with up to 90% of the sodium being retained at the highest concentration of trehalose tested (500 mM). As also shown in that figure, vesicles dehydrated without prior freezing retain more of their contents than those frozen in liquid nitrogen. That is, dehydration without freezing is overall a gentler process than dehydration with freezing.
The ability of trehalose to protect liposomes during dehydration/rehydration is further illustrated by the freeze-fracture electron micrographs of Figure 2 which shows liposomes before (Fig. 2a -- Control) and after ~Fig. 2b -- Freeze Dried~ dehydration/rehydration with prior freezing. The trehalose concentration in this case was 250 mM. As can been seen in this figure, the appearance of the liposome population is essentially unchanged by the dehydration/rehydratlon process, that is, the trehalose successfully protects the liposomes during this process.
Experiments performed without any trehalose in the solute solution gave a milky suspension upon rehydra~ion in contrast to the opulescent appearance of the original sample. In addition, recovery of veslcles from the 1 ml Sephadex columns used to strip unencapsulated 22Na was low (less than 10%), indicating that the liposomes had fused to form larger structures.
Figure 3 shows the effects of varying the trehalose concentration. Fig. 3a shows the liposomes prior to drying, while Fig. 3b shows them after drying and rehydration in the absence of trehalose. As is evident from these figures, the original vesicles are small and uniform in size, while the dehydrated/rehydrated vefiicles are in general much larger.
Fig. 3c and Fig. 3d show liposomes which have been dried and rehydrated in the presence of 50 mM and 125 mM trehalose, respectively. As shown by these figures, vesicles dried in the presence of 50 mM trehalose and then rehydrated are generally the same size as prior to dehydration, but a small fraction of larger -16 ~Z~36~
structures are also observed. At trehalose concentrations of 125 mM or greater, there is no discernible structural difference between veslcles before and after dehydration and rehydration.
To verify that vesicles dehydrated in the presence of trehalose retain their contents and do not simply re-encapsulate label upon rehydration, vesicles were prepared in 250 mM
trehalose, and 22Na was then added to the external medium.
Following dehydration and rehydration, aliquots of the suspension were passed down 1 ml Sephadex columns as described in Materials and Methods above. Of the available 22Na , less than 0.02~ was sequestered by the rehydrated vesicles, confirming that they do not encapsulate solute in the external medium upon rehydration.
The ability of dehydrated ETVs to retain inulin (molecular weight 5000) is shown as a function of trehalose concentration in Figure 4. A comparison of that figure with Figure 1, reveals that for the same trehalose concentration, more of the high molecular weight inulin is retained than the low molecular weight sodium.
However, at the higher trehalose concentrations, the difference is quite small, suggesting that the small amount of each label lost may be the result of vesicle rupture rather than permeability changes.
The ability of ETVs to retain the antitumor drug adriamycin when dehydrated in the presence of trehalose is shown in Table 1.
The data presented in this table was obtained as follows: Rgg phosphatidylcholine ETVs were prepared as described above using a solute solution (169 mM KGlu, 20 mM HEPES (pH 7.4), 40 umol lipid/ml) containing 250 mM trehalose. Subsequently, the external potassium buffer was exchanged for a sodium buffer (150 mM NaCl, mM HEPES (pH 7.4), 250 mM trehalose). Adriamycin (200 nmol/umol lipid) was added, along with valinomycin (0.5 ug/umol lipid) to induce a membrane potential. After a 2 hour incubation, unencapsulated adriamycin was removed by passing the vesicles through a column of Sephadex G-50 equilibrated with the trehalose-containing sodium buffer described above. The ETVs were dehydrated for 24 hours without prior freezing and then rehydrated as described above.
~ 83~
The amounts of ertrapped adriamycin in the vesicles both before and after dehydration/rehydration, as well as the rate of arug leakage from the vesicles, were measured by first passing 100 ul aliquots of the vesicle suspension over columns (1 ml) of Sephadex G-50 to remove any untrapped msterial (see Canadian Patent Application No. 483,485 for further details). Trapped adriamycin was then quantitated by mixing an aliquot of the vesicle suspension with 0.5~ Triton X-lOO (which disrupted the vesiclss and released the trapped drug) and monitoring the absorbance at 480 nm employing a Pye Unicam SP8~200 spectrophotometer. Since the colùmns tend to trap a small percentage of the liposomes applied thereto, the measured values for the amounts of encapsulated material retained after the de-hydration/rehydration process are somewhae lower than the levels actually achieved.
The results of these ~xperimen~s are shown in Table 1. As shown therein, more than 90% of the drug is retained following dehydration and rehydration, i.e. ehe same levels as those achieved with 22Na and 3H-lnulln. Moreover, the rate of leakage of adriamycin fro~ the rehydrated vesicles is comparable to che rate observed wlth vesicles which have not been dehydrated (see Bally, et al., (1985), Biochi~. Biophys. Acta., 812:66).
As cleasly demonstra~ed by ehis Example, the sugar trehalose ls capable of protecting liposomes during dehydration and subsequent rehydratlon so that more than 90~ of the material encapsulated withln the liposomes is still retained therein after rehydraeion.
` Exa~ple 2 Exposure of Both the Inside ant Outside Surfaces of Liposome Membranes to a Proeective Su~ar This example illustrates the enhanced protective effect achieved by having a protective suga. (trehalose) in contact with both the internal and external surfaces of the liposome membranes.
ETVs were prepared with trehalose on both sides of the membrane (by including trehalose in ehe solute solution used to form che vesicles) or only on the outside of the membrane (by * Trade Mark 6~
excluding trehalose from the solute solution and adding it to the external medium after the vesicles had been formed). The vesicles were dehydrated and at various poines i~ time, up to 72 hours, samples were rehydrated and the level of 22Na retained determined. The results are shown in Table 2, together witk values for the amount of residua~l water present in the samples following dehydration.
As shown by this table, maximum protection is achieved when the protective sugar i9 present on both membrane surfaces. Also, when only the external surface is exposed to the protective sugar, the amount of structural damage which the vesicles undergo is related to the amount of residual water present in samples.
Example 3 Effects of Vesicle Size And Salt Concentration _ _ This example describes the effects of various vesicle sizes and salt concentrations on the ability of trehalose to protect vesicles during dehydration and rehydration.
ETVs of various sizes were produced using polycarbonate filters having pore sizes ranging from 50 nm to 800 nm. The ETVs were subjected to a freeze-thaw cycle as described above in "Materials and Methods." The mean diameters of the resulting vesicles as measured by quasi-elastic light scattering are given in Table 3.
As shown by the data in Table 3, the ability to retain Na is relatively insensitive to vesicle size. Moreover, since the larger vesicles contained some muItilamellar structure 9 this data illustrates that sugar protection is achieved for multilamellar vesicles. Although the data in Table 3 indicates that the most stable vesicles would appear to be those with a mean diameter of about 170 nm, the multilamellar structure of the larger vesicles makes a rigorous comparison difficult.
The effects of varying the salt concentration of the internal and external media for a fixed trehalose concentration is shown in Figure 5. As shown therein, there is a small but significant :
``` -19- ~336~
increase in the amount of Na retained in the vesicles with higher salt concentrations.
Example 4 Relative Ability of Trehalose and Other Sugars to Protect Vesicles during Dehydration This example illustrates the relative ability of trehalose and other sugars to protect vesicles during dehydration.
Vesicles were prepared in 500 mM trehalose, maltose, lactose~
sucrose, and glucose and the amount of Na retained by the ves-; lO icle following dehydration and rehydration determined. As shown in Table 4, trehalose and sucrose were the most effective followed by maltose, glucose and lactose.
Example 5 Dehydration of Liposomes Using the Protective Sugar Streptomycin This example illustrates the ability of the sugar streptomy-cin to protect liposomes from substantial loss of their internal contents during dehydration and subsequent rehydration. Experi-ments demonstrating high retention of H-inulin were performed.
In particular9 egg phosphatidylcholine monophasic vesicles (MPVs) were prepared as described in commonly assigned U.S. Pat-ent No. 4,588,578 entitled "Lipid Vesicles Prepared in a Mono-phase". A complete description of the technique used in this ex-ample appears in that patent.
Briefly, 127 umoles of egg phosphatidylcholine were used in the vesicle preparation. H-inulin and various concentrations of streptomycin were added to phosphate buffered saline (PBS) lacking divalent cations (pH 7.3), and MPVs were formed. The MPVs were dehydrated with prior freezing, rehydrated in PBS and assayed for retained H-inulin as described above. The results are shown in Table 5.
As shown in this table, the amount of H-inulin retained in the vesicles after rehydration depends on the streptomycin ~;~83G~L
concentration, with up to 86% of the inulin being r~tained at ~he highest concentration of streptomycin tested (568 mM).
The ability of dihydrostreptomycin to protect liposomes during dehydration/rehydration was also tested following essentially the same protocol as that used with streptomycin except that washing of the ~Vs was done with PBS lacking dihydrostreptomycin so that dihydrostreptomycin was only included as part of the internal conten~s of the finished liposomes. In this case a retention level of 63% was observed for a dihydrostreptomycin concentration level of 565 mM.
Example 6 Loading of Rehydrated Liposomes ~sing Transmembrane Potentals This example illustrates: 1) that liposomes having a concentration gradient across their membranes can be dehydrated in the presence of a protective sugar and rehydrated without loss of the concentration gradient; and 2) that after rehydration, the concentration gradient can be used to load a charged material (the ; drug adriamycin) into the liposomes.
~esicles having a Na -K chemical gradient across their membranes were prepared by forming ETVs in a potassium glutamate buffer (169 mM potassium glutamate, 250 mM trehalose, 20 mM HEPES, pH 7.4), and then replacing the external buffer with a ~aCl buffer (150 mM NaCl, 250 mM trehalose, 20 mM HEPESJ pH 7.4) by passing the vesicles through a Sephadex G-50 (fine) column (1.4 x 10 cm) which had been pre-equilibrated with the NaCl solution. Where employed, valinomycin (Sigma, St. Louis, Missouri) was added in ethanol to a concentration of 0.5 ug/umole phospholipid.
Similarly, transmembrane pH gradients (interior acid) were formed by preparing the liposomes in a buffer with low pH (135 mM
glutamic acid, 250 mM trehalose, brought to pH 5.5 by the addition of potassium hydroxide) which was then exchanged with a high pH
buffer (125 mM glutamic acid, 30 mM NaCl, 250 mM trehalose, brought to pH 7.5 by the addition o~ potassium hydroxide) on a ; 35 S~phadex G-50 (fine) column. Where used, the proton ionophore CCCP was added to a final concentration of 20 uM.
- ~%~3360~
Transmembrane potentials were measured by determining the distribution of the lipophilic cation 3H-tetraphenylphosphonium bromide ( H-TPPB, NEN, Canada). Specifically, 1 uCi of H-TPPB in 1 ul ethanol was added to a 1-2 ml sample of the ETV dispersion and the mixture was incubated at 20C for 20 minutes. An aliquot (100 ul) was withdrawn and the untrapped 3H-TPP was removed by loading the aliquot onto a Sephadex G-50 column packed in a 1 ml disposable syringe, and then centrifuging the column at 500 g for 3 minutes to elute the vesicles. The trapped H-TPP was determined by liquid scintillation counting, and the phospholipid determined by phosphate assay.
Using trapped volume values (ul per umol of phospholipid) for the ETVs determined by measuring the amount of 22~a or 3H-inulin captured in the ETVs by the ~TV process, the concentrations of 3H-TPP inside [ H-TPP ]i and outside [3H-TPP ] the vesicles were calculated, from which the transmembrane potential (Vm) was calculated using the Nernst e~uation:
V = - 59 log [3H-TPP ]i/[3H-TPP ]O~
Both the Na /K and the pH gradient vesicles were dehydrated ; 20 under high vacuum for 24 hours and then rehydrated. Control vesicles were kept at ~C for 24 hours. Pollowing drying and rehydration, the transmembrane potentials exhibited by these vesicles in the presence and absence of ionophores were compared to the transmembrane potentials generated by the controls, also in the presence and absence of ionophores. The results are shown in Figures 6 (pH) and 7 (Na /K ).
As can be seen from these figures, the transmembrane potentials exhibited by the vesicles which had been dehydrated and ~ then rehydrated are essentially identical to those exhibited by - 30 the controls. The only apparent difference is that in the case of the pH gradient vesicles, the transmembrane potentials for the dehydrated/rehydrated vesicles develop somewhat slower than the transmembrane potentials for the control vesicles.
The ability of the Na /K vesicles to accumulate adriamycin after dehydration and rehydration was tested in the presence and absence of the ionophore valinomycin, and compared with the "`` ~2~3~
accumulation exhibited by ehe control vesicles, i.e., the vesicles which had been stored at 4C for ~4 hours rather than being dehydrated for 24 hours. Sufficient adrlamycin was added to the vesicles' external medium to produce a final concentration of 0.2 moles adriamycin per mole of phospholipid.
The results of these tests are shown in Figure 8. As can be seen therein, the dehydrated/rehydrated vesicles accumulate adriamycin essentially at the same rate and to the same extent as the control vesicles.
Although not wishing to be bound by any particular theory of operation, one of the mechanisms involved ln the observed uptake of adriamycin in response to Na /K gradients may involve the pH
gradients which are automatically generated in response to such gradients due to the per~eability of liposome membranes to H+
ions. In accordance with this mechanism, adriamycin passes through the membrane in an uncharged state, with its internal and external concentrations being a function of the internal and external H ion concentrations, the internal concentration being high when the lnternal H concentration is high, and vice versa.
In sum, this example demonstrates that delayed loading of vesicles can be accomplished through the combination of concentration gradients and the dehydration/rehydration process.
Example 7 Dehydra~ion of Liposomes Having Mul~ple Lipid Layers Without_Prior Freezin~ and Without the Use of a Protective Sugar This example illustrates that liposomes having multiple lipid layers will retain a substantial portion of their internal contents during dehydration and subsequent rehydration, even without the use of a protective sugar, provided that the dehydration is performed without prior freezing of the liposomes and provided that the dehydration is performed to an end point where there is sufficient water left in the preparation so that a substantial portion of the membranes retain their integrity upon rehydration.
~8~
The experiments were performed using the following types of liposomes, all of which include multiple lipid layers: multila-mellar liposomes (MLVs), stable plurilamellar liposomes (SPLVs), and monophasic vesicles (MPVs). A detailed description of suit-able techniques for producing SPLVs and MPVs appears in commonly assigned U.S. Patents Nos. 4,522,803 and 4,588,578. Descriptions of methods for preparing MLVs can be found throughout the litera-ture, including, for example, the Liposome text (Marc J. Ostro, ed., 1983) and the Szoka, Jr., et al. reference (Ann. Ref. Bio-phys. Bioengr., 1980), referred to above.
The materials and experimental protocol used were as fol-lows. All three types of liposomes were made with egg phosphati-dylcholine tEPC) obtained from Sigma Chemical Company and with Hepes buffer with and without trehalose (i.e., 20 mM Hepes, 150 mM NaCl, pH 7.4 -- Buffer O; or 20 mM Hepes, 150 mM NaCl, 250 mM
trehalose, pH 7.4 -- Buffer 250). CrO4 (New ~ngland Nuclear) in normal saline was used as the tracer. 0.01 ml of the tracer produced a cpm level of approximately 500,000.
For each of the three types of liposomes, the EPC was dis-solved in CHC13 (100 mg/ml) and 3.14 ml of the resulting solu-tion was deposited on the sides of a glass, round bottom flask using a Rotovap evaporator. To make SPLVs, the lipid was redis-solved in ether (10 ml) to which was added 0.5 ml of either Buf-fer O or Buffer 250 which included 0.01 ml of the tracer solution.
The ether was blown off under a stream of nitrogen while sonicat-ing in a bath sonicator. 4.5 ml of Buffer O or Buffer 250 was then added, producing a final lipid concentration of 62.8 mg/ml.
To make MPVs, the lipid was redissolved in 100% ethanol (10 ml) to which was added 0.5 ml of either Buffer O or Buffer 250 which included 0.01 ml of the tracer solution. The ethanol was evaporated off at 55-60C using a Rotovap evaporator. 4.5 ml of * Trade Mark ~2836~L
-~4-Bufter O or Buffer 250 was then added, producing a final lipid concentration of 62.8 mg/ml.
MLVs were made by adding 5.0 ml of Buffer O or Buffer 250 to the round bottom flask and then vortexing the samples with glass beads for approximately 5 minuees. The buffers included 0.0~ ml of the tracer solueion. As with the SPLVs and the MPVs, the final lipid concentration was 62.8 mg/ml.
Once all six liposomes samples had been prepared (on~ with and one without trehalose for each of the three types of liposomes), they were removed from the round bottom flasks by vortexlng for approximately 5 minutes, and each sample was placed in a dlalysis bag made of Thomas 12,000 M.W. dialysis tubing.
The radioactivity of each bag was counted and the bags were then dialyzed against 500 ml of Buffer O or Buffer 250, as appropriate, until a stable count was reached indicating that the tracer had been removed from ehe external medium surrounding the liposomes.
Dialysls for approxlmately 24 hours was found sufficient to reach a stable count.
Without prior freezing, 1.0 milliliter of each sample was drled for 24 hours in a 10 ml Kimex tube at room temperature under high vacuum using a Virtis Freeze Drier (Gardiner, N.Y.). As the results presentet belo~ for the liposome preparations which did not include trehalose show, dehydration for this period of time and under these conditions resulted in dehydrated preparaeions which lncluded sufficlent residual water so that a substantial portion of the liposome membranes retained their ineegrity upon rehydration even though a protective sugar was not used.
After dehydration, the lipo~omes were placed in 0.9 ml of distilled water and slo~ly rehydrated with gentle swirling or vortexing, as neces-qary.
The rehydrated liposo~es were transferred to dialysis bags of the type describet above and their ratioactivity measured. The bags were then dialyzed agalnst Buffer O or Buffer 250, as appropriate, for approximately 18 hours and their radioactivity measured again. The a~ount of radioactlvlty retained by the liposomes after dialysis was used as a measure of the amount of * Trade Mark ~ ~%~33~ 014 internal contents which the liposomes were able to retaln through the dehydratlon/rehydraLion process. As a control, 1.0 mllllliter or each sample was placed in a 10 ml Rimex tube, held at room temperature without drying for 24 hours, placed in a dialysis bag, measured for radioactivlty, dialyzed against the appropriate buffer, and then remeasured for radloactivity.
The results of these experiments were as follows, where the percentages given are the counts per minute after dialysls relative to the counts per minute before dialysis and where the numbers in parentheses are the control values:
O_Buffer 250 Buffer MLVs 91.9~ (87.7%) 84.4~ (100.1~) SPLVs 85.1~ (82.7%) 84.3% (94.2~) MPVs 85.5% (90.1~) 75.9% (93.2%) As shown by these results, well over 80~ of the lnternal coneents of each of the three types of liposo~es was retained after the dehydration/rehydration process without ~he use of any protective sugars. Moreover, addlng trehalose to these types of liposomes somewhat decreased, rather than increased, the amount of internal contents retained in the liposomes after the dehydration/rehydration process.
Dehydratlon of Liposo~es Without The Use of a Protectlve Suvar . . _ ~
Quantlflcation of Preferred Residual Water Levels This example illustrates that when a llposome preparation is dehydrated without the use of a proeective sugar, at least about 2%, and preferably between about 2% and about 5~, of the original water in the preparation should remain in the preparation at the end of the dehydration process so that the liposomes will retain a substantial portion of their internal contents upon rehydration.
The experiments were perfor~ed using stable plurila~ellar liposomes (SPLVs) and freeze and thaw multilamellar vesicles (FAT~LVs), both of which include multiple lipid ~ayers. A
detailed description of suitable techniques for producing SPLVs appears in U.S. Patent No. 4,522,803, referred to -26 ~3~
above. See also, Grunner et al., (1985) Biochemistry, 24:2833.
A description of techniques for producing FATMLVs can be found in copending and commonly assigned Canadian Patent Application No. 520,029.
The materials and experimental protocol used were as fol-lows. Egg phosphatidylcholine (99%) was purchased from Avanti Polar Lipids, Inc. (Birmingham, Alabama). [ C]inulin and tri-tiated water were obtained from New England Nuclear (Boston, Massachusetts). Tritiated water and [ C]inulin were counted in a Beckman LS6800 liquid scintillation counter set for 2 channel operation. All data were corrected for isotope counting effici-ency and channel spillover.
SPLVs were prepared by adding 400 umoles of egg PC in chloro-form to a 100 ml round bottom flask. Bulk solvent was removed by evaporation for approximately 2 minutes using a Rotovap evapora-tor; the lipid was not taken to dryness. Ten milliliters of an-hydrous diethyl ether (J.T. Baker Chemical Co., Phillipsburg, New Jersey) was added to the flask to redissolve the lipid. To this solution was added 0.3 ml of equimolar 145 mM NaCl/KCl with 20 mM
HEPES (pH 7.4) containing [ C]inulin (16.67 uCi/ml, specific ac-tivity 2.4 mCi/g) and unlabeled inulin to bring the final inulin concentration to 1.42 umol inulin/0.3 ml buffer. The samples were sonicated for 1 minute for dispersion and then dried with N2 while sonicating until the odor of ether was no longer detectable. The lipid was resuspended in 10 ml of buffer and transferred to a 30 ml Corex tube.
Unentrapped [14C]inulin was removed by 4 washlcentrifugation cycles, the centrifugation being conducted for 30 minutes at 12,100 x g in a Beckman J2-21 centrifuge with a JA-20 rotor. The first wash was performed with 10 ml, and subsequent washes with 20 ml, of buffer.
After decanting the final wash supernatant, the vesicle pel-let was resuspended with 5 ml of buffer containing tritiated water (2.5 uCi/ml, specific activity 1 mCi/g). The lipld .
* Trade Mark concen~ration of this preparation was determined by dividing the amoune of lipid used (400 umol) by the measured volume of the preparation. For the SPLV Liposomes, the average volume was 6.01 + 0.04 ml, glving an average lipld concentration of 6.65 x 10 5 moles lipid/m]
The radioactivity of the tritiated buffer used to resuspend the vesicles was measured and found to be 5.55 x 106 dpm/ml (dpm =
disintegrations per minute). To be able to calculate residual water values ln the dehydrated preparations in terms of moles of water per mole of lipid (see below), this dpm/ml value was converted to a moles H2OIdpm value by dividing the dpm/ml value by the conceneration of water in the buffer. For this purpose, the buffer was assumed to be pure water 90 thae the concentration of water was 5.55 x 10 2 moles H20/ml. The moles ~ 0/dpm value was thus calculated to be 1.00 x 10 8 moles H2O/dpm.
After resuspension in the tritiated buffer, the preparation was held for a period of at least 30-60 minutes at room temperature prior to dehydra~ion to allow the tritiated water to equilibrate throughout the preparatlon.
FATMLVs were prepared by adding 400 umoles of ~gg PC ln chloroform to a 100 ml round bottom flask. Solvent was removed by rotary evaporation for 5 minute~, followed by 2 hours under high vacuum in a dessicator (see dehydration dlscussion below for a description of the specific equipment used).
The llpid was hytrated with 5 ml of equlmolar 145 mM NaCl/KCl and 20 mM Hepes (pH 7.4) containing [14C]inulin (I uCi/ml, speciflc activity 2.4 mCi/g) ant unlabeled inulln to bring the final lnulin concentration to 1.08 mM.
The mixture was dlspersed by vortexing and aliquots were transferred to 1.8 ml Nunc cryo tubes (Nunc, Denmark). The samples were successively fro~en in liquid nitrogen and thawed in war~ water five times. The content~ were pooled, mixed and transferred to a 30 ml Corex tube.
Unencapsulated [14C]inulin was removed by 4 wash/centrifugation cycles, usin~ 20 ml of buffer for each wash. The centrifugations were performed ln the manner described above for SPLVs.
* Trade Mark 12~33G04 After decanting the final wash supernatant, the vesicle pellet was resuspended with 5 ml of the qame tritiated waeer buffer used to resuspend the SPLVs. The final preparation was held for a period of at least 30-60 minutes prior to dehydration to allow the tritiated water to equilibrate throughout the preparation. As with the SPLV experiments, the lipid concentration of the preparation was determined by dividing the amount of lipid used (400 umol) by the measured volume of the preparation. In this case, the average volume was 7.13 + 0.06 ml, giving an average lipid concentration of 5.60 x 10 5 moles lipid/ml.
The radioactivity due to tritiated water of aliquots of the resuspended SPLVs and FATMLYs was measured and an average value of
The mixture was dispersed by vortexing and then passed ten times through two stacked polycarbonate filters of 100 nm pore size (Nuclepore, Inc., Pleasanton, CA) using a pressure of 250 psi. In those cases where a freeze-thaw procedure was utilized, the vesicles were prepared as above, freeze-thawed once using liquid nitrogen, and then again repeatedly passed through the stacked flleers.
; Unencapsulated 22Na+ or 3H-inulin was removed by passing thevesicles through a column (1.4 x 10 cm) of either Sephadex C-50 (fine) for removal of 22Na or Ultragel AcA 34 for removal of H~inulin. This procedure generally diluted the phospholipid coneent of the sample by approximately S0~ to sive a concentration of about 20 umoles phospholipld per mlllillter.
Sample~ (1 ml) were dried in 10 m~ Kimex tubes at room temperature under high vacuum using a Virtis Freeze Drler ~Cardiner, N.Y.). In some cases, the samples were frozen in ; llquid nitrogen prior to dehydration. In either case, the reducedpressure dehydration process was carried out for approximately 24 hours.
Rehydration Followlng dehydration and storage for perlods ranging from 1 to 7 days, the samples were rehydrated with diseilled water (900 ul) and the vesicles dlspersed by gentle vortexing. The amount of entrapped 2Na , 3H-inulin or adriamycin remainin8 wiehin the vesicles was measured uslng the techniques described below (see 'Assays") after passage of 100 ul aliquots of the vesicle suspension over columns (1 ml) of Sephadex G-50 (fine) or ~ltragel AcA 34, equilibrated with the same solution in which the vesicles were suspended, to remove any untrapped materlal (see Canadian * Trade Mark 1l :28~6~4 Patent Application No. 483,485 for furthe~ details). Since the columns tend to trap a small percentage of the liposomes applied thereto, the values reported oelow for the amounts of encapsulated material retalned after the dehydration/rehydration process are somewhat lower than the levels actually achieved by the procedures of the present inventlon.
Free~e Fracture Electron Microscop~
Samples for freeze-fracture contained 25~ glycerol and were fractured and replicated following the procedures described in Madden, T.D., Hope, M.J. and Cullis, P~R. (1983) Biochemistry 22, 1970-1974, using a Balzers freeze-fracture apparatus. Replicas were visuali~ed on a Phillips 400 electron microscope.
Quasi-Elastic Light Sca~ttering Measurements *
Vesicles were slzed employing a Nicomp 200 Laser Particle Sizer (Nicomp lnstrument, Goleta, CA) operating at 632.8 nm and 5 ;nW.
~ Assays ; Phospholipids were quantified by determination of inorganic phosphorus as described by Chen, et al., (1956) Anal. Chem.
28:1756. Adrlamycin uptake was measured following solubilization of vesicles in 0.5% Triton X-lOQ from its absorbance at 480 nm.
3H-inulin, 3H-H20 and 3H-tetraphenylphosphonium were counted in a Phillips PW 4700 liquid scintillation counter, while 22Na was *
quantlfied by gam~a counting on a Beckman Gamma 800.
Example 1 Dehydration of_Liposomes Usin~the Protective Sugar Trehalose This example illuseraees the ability of ehe sugar ~rehalose eO protect liposomes from substantial loss of their internal contents during dehydraeion and subsequent rehydration.
Experimenes demonstrating high reteneion levels for 22Na , H-inulin, and adriamycin were performed. The results are shown in Figures 1-4 and Table 1.
In particular, egg phosphatidylcholine ETVs were prepared as described above using solute solueions containing 22~a and various concentratlons of trehalose. The ETVs were dehydrated * Trade Mark -15- ~L2836~4 with or without prior freezlng in liquid nitrogen, rehydrated and assayed as described above. The results are shown in Figure 1.
As shown in that figure, the amount of 22Na retainsd in the vesicles after rehydration depends on the trehalose concentration, with up to 90% of the sodium being retained at the highest concentration of trehalose tested (500 mM). As also shown in that figure, vesicles dehydrated without prior freezing retain more of their contents than those frozen in liquid nitrogen. That is, dehydration without freezing is overall a gentler process than dehydration with freezing.
The ability of trehalose to protect liposomes during dehydration/rehydration is further illustrated by the freeze-fracture electron micrographs of Figure 2 which shows liposomes before (Fig. 2a -- Control) and after ~Fig. 2b -- Freeze Dried~ dehydration/rehydration with prior freezing. The trehalose concentration in this case was 250 mM. As can been seen in this figure, the appearance of the liposome population is essentially unchanged by the dehydration/rehydratlon process, that is, the trehalose successfully protects the liposomes during this process.
Experiments performed without any trehalose in the solute solution gave a milky suspension upon rehydra~ion in contrast to the opulescent appearance of the original sample. In addition, recovery of veslcles from the 1 ml Sephadex columns used to strip unencapsulated 22Na was low (less than 10%), indicating that the liposomes had fused to form larger structures.
Figure 3 shows the effects of varying the trehalose concentration. Fig. 3a shows the liposomes prior to drying, while Fig. 3b shows them after drying and rehydration in the absence of trehalose. As is evident from these figures, the original vesicles are small and uniform in size, while the dehydrated/rehydrated vefiicles are in general much larger.
Fig. 3c and Fig. 3d show liposomes which have been dried and rehydrated in the presence of 50 mM and 125 mM trehalose, respectively. As shown by these figures, vesicles dried in the presence of 50 mM trehalose and then rehydrated are generally the same size as prior to dehydration, but a small fraction of larger -16 ~Z~36~
structures are also observed. At trehalose concentrations of 125 mM or greater, there is no discernible structural difference between veslcles before and after dehydration and rehydration.
To verify that vesicles dehydrated in the presence of trehalose retain their contents and do not simply re-encapsulate label upon rehydration, vesicles were prepared in 250 mM
trehalose, and 22Na was then added to the external medium.
Following dehydration and rehydration, aliquots of the suspension were passed down 1 ml Sephadex columns as described in Materials and Methods above. Of the available 22Na , less than 0.02~ was sequestered by the rehydrated vesicles, confirming that they do not encapsulate solute in the external medium upon rehydration.
The ability of dehydrated ETVs to retain inulin (molecular weight 5000) is shown as a function of trehalose concentration in Figure 4. A comparison of that figure with Figure 1, reveals that for the same trehalose concentration, more of the high molecular weight inulin is retained than the low molecular weight sodium.
However, at the higher trehalose concentrations, the difference is quite small, suggesting that the small amount of each label lost may be the result of vesicle rupture rather than permeability changes.
The ability of ETVs to retain the antitumor drug adriamycin when dehydrated in the presence of trehalose is shown in Table 1.
The data presented in this table was obtained as follows: Rgg phosphatidylcholine ETVs were prepared as described above using a solute solution (169 mM KGlu, 20 mM HEPES (pH 7.4), 40 umol lipid/ml) containing 250 mM trehalose. Subsequently, the external potassium buffer was exchanged for a sodium buffer (150 mM NaCl, mM HEPES (pH 7.4), 250 mM trehalose). Adriamycin (200 nmol/umol lipid) was added, along with valinomycin (0.5 ug/umol lipid) to induce a membrane potential. After a 2 hour incubation, unencapsulated adriamycin was removed by passing the vesicles through a column of Sephadex G-50 equilibrated with the trehalose-containing sodium buffer described above. The ETVs were dehydrated for 24 hours without prior freezing and then rehydrated as described above.
~ 83~
The amounts of ertrapped adriamycin in the vesicles both before and after dehydration/rehydration, as well as the rate of arug leakage from the vesicles, were measured by first passing 100 ul aliquots of the vesicle suspension over columns (1 ml) of Sephadex G-50 to remove any untrapped msterial (see Canadian Patent Application No. 483,485 for further details). Trapped adriamycin was then quantitated by mixing an aliquot of the vesicle suspension with 0.5~ Triton X-lOO (which disrupted the vesiclss and released the trapped drug) and monitoring the absorbance at 480 nm employing a Pye Unicam SP8~200 spectrophotometer. Since the colùmns tend to trap a small percentage of the liposomes applied thereto, the measured values for the amounts of encapsulated material retained after the de-hydration/rehydration process are somewhae lower than the levels actually achieved.
The results of these ~xperimen~s are shown in Table 1. As shown therein, more than 90% of the drug is retained following dehydration and rehydration, i.e. ehe same levels as those achieved with 22Na and 3H-lnulln. Moreover, the rate of leakage of adriamycin fro~ the rehydrated vesicles is comparable to che rate observed wlth vesicles which have not been dehydrated (see Bally, et al., (1985), Biochi~. Biophys. Acta., 812:66).
As cleasly demonstra~ed by ehis Example, the sugar trehalose ls capable of protecting liposomes during dehydration and subsequent rehydratlon so that more than 90~ of the material encapsulated withln the liposomes is still retained therein after rehydraeion.
` Exa~ple 2 Exposure of Both the Inside ant Outside Surfaces of Liposome Membranes to a Proeective Su~ar This example illustrates the enhanced protective effect achieved by having a protective suga. (trehalose) in contact with both the internal and external surfaces of the liposome membranes.
ETVs were prepared with trehalose on both sides of the membrane (by including trehalose in ehe solute solution used to form che vesicles) or only on the outside of the membrane (by * Trade Mark 6~
excluding trehalose from the solute solution and adding it to the external medium after the vesicles had been formed). The vesicles were dehydrated and at various poines i~ time, up to 72 hours, samples were rehydrated and the level of 22Na retained determined. The results are shown in Table 2, together witk values for the amount of residua~l water present in the samples following dehydration.
As shown by this table, maximum protection is achieved when the protective sugar i9 present on both membrane surfaces. Also, when only the external surface is exposed to the protective sugar, the amount of structural damage which the vesicles undergo is related to the amount of residual water present in samples.
Example 3 Effects of Vesicle Size And Salt Concentration _ _ This example describes the effects of various vesicle sizes and salt concentrations on the ability of trehalose to protect vesicles during dehydration and rehydration.
ETVs of various sizes were produced using polycarbonate filters having pore sizes ranging from 50 nm to 800 nm. The ETVs were subjected to a freeze-thaw cycle as described above in "Materials and Methods." The mean diameters of the resulting vesicles as measured by quasi-elastic light scattering are given in Table 3.
As shown by the data in Table 3, the ability to retain Na is relatively insensitive to vesicle size. Moreover, since the larger vesicles contained some muItilamellar structure 9 this data illustrates that sugar protection is achieved for multilamellar vesicles. Although the data in Table 3 indicates that the most stable vesicles would appear to be those with a mean diameter of about 170 nm, the multilamellar structure of the larger vesicles makes a rigorous comparison difficult.
The effects of varying the salt concentration of the internal and external media for a fixed trehalose concentration is shown in Figure 5. As shown therein, there is a small but significant :
``` -19- ~336~
increase in the amount of Na retained in the vesicles with higher salt concentrations.
Example 4 Relative Ability of Trehalose and Other Sugars to Protect Vesicles during Dehydration This example illustrates the relative ability of trehalose and other sugars to protect vesicles during dehydration.
Vesicles were prepared in 500 mM trehalose, maltose, lactose~
sucrose, and glucose and the amount of Na retained by the ves-; lO icle following dehydration and rehydration determined. As shown in Table 4, trehalose and sucrose were the most effective followed by maltose, glucose and lactose.
Example 5 Dehydration of Liposomes Using the Protective Sugar Streptomycin This example illustrates the ability of the sugar streptomy-cin to protect liposomes from substantial loss of their internal contents during dehydration and subsequent rehydration. Experi-ments demonstrating high retention of H-inulin were performed.
In particular9 egg phosphatidylcholine monophasic vesicles (MPVs) were prepared as described in commonly assigned U.S. Pat-ent No. 4,588,578 entitled "Lipid Vesicles Prepared in a Mono-phase". A complete description of the technique used in this ex-ample appears in that patent.
Briefly, 127 umoles of egg phosphatidylcholine were used in the vesicle preparation. H-inulin and various concentrations of streptomycin were added to phosphate buffered saline (PBS) lacking divalent cations (pH 7.3), and MPVs were formed. The MPVs were dehydrated with prior freezing, rehydrated in PBS and assayed for retained H-inulin as described above. The results are shown in Table 5.
As shown in this table, the amount of H-inulin retained in the vesicles after rehydration depends on the streptomycin ~;~83G~L
concentration, with up to 86% of the inulin being r~tained at ~he highest concentration of streptomycin tested (568 mM).
The ability of dihydrostreptomycin to protect liposomes during dehydration/rehydration was also tested following essentially the same protocol as that used with streptomycin except that washing of the ~Vs was done with PBS lacking dihydrostreptomycin so that dihydrostreptomycin was only included as part of the internal conten~s of the finished liposomes. In this case a retention level of 63% was observed for a dihydrostreptomycin concentration level of 565 mM.
Example 6 Loading of Rehydrated Liposomes ~sing Transmembrane Potentals This example illustrates: 1) that liposomes having a concentration gradient across their membranes can be dehydrated in the presence of a protective sugar and rehydrated without loss of the concentration gradient; and 2) that after rehydration, the concentration gradient can be used to load a charged material (the ; drug adriamycin) into the liposomes.
~esicles having a Na -K chemical gradient across their membranes were prepared by forming ETVs in a potassium glutamate buffer (169 mM potassium glutamate, 250 mM trehalose, 20 mM HEPES, pH 7.4), and then replacing the external buffer with a ~aCl buffer (150 mM NaCl, 250 mM trehalose, 20 mM HEPESJ pH 7.4) by passing the vesicles through a Sephadex G-50 (fine) column (1.4 x 10 cm) which had been pre-equilibrated with the NaCl solution. Where employed, valinomycin (Sigma, St. Louis, Missouri) was added in ethanol to a concentration of 0.5 ug/umole phospholipid.
Similarly, transmembrane pH gradients (interior acid) were formed by preparing the liposomes in a buffer with low pH (135 mM
glutamic acid, 250 mM trehalose, brought to pH 5.5 by the addition of potassium hydroxide) which was then exchanged with a high pH
buffer (125 mM glutamic acid, 30 mM NaCl, 250 mM trehalose, brought to pH 7.5 by the addition o~ potassium hydroxide) on a ; 35 S~phadex G-50 (fine) column. Where used, the proton ionophore CCCP was added to a final concentration of 20 uM.
- ~%~3360~
Transmembrane potentials were measured by determining the distribution of the lipophilic cation 3H-tetraphenylphosphonium bromide ( H-TPPB, NEN, Canada). Specifically, 1 uCi of H-TPPB in 1 ul ethanol was added to a 1-2 ml sample of the ETV dispersion and the mixture was incubated at 20C for 20 minutes. An aliquot (100 ul) was withdrawn and the untrapped 3H-TPP was removed by loading the aliquot onto a Sephadex G-50 column packed in a 1 ml disposable syringe, and then centrifuging the column at 500 g for 3 minutes to elute the vesicles. The trapped H-TPP was determined by liquid scintillation counting, and the phospholipid determined by phosphate assay.
Using trapped volume values (ul per umol of phospholipid) for the ETVs determined by measuring the amount of 22~a or 3H-inulin captured in the ETVs by the ~TV process, the concentrations of 3H-TPP inside [ H-TPP ]i and outside [3H-TPP ] the vesicles were calculated, from which the transmembrane potential (Vm) was calculated using the Nernst e~uation:
V = - 59 log [3H-TPP ]i/[3H-TPP ]O~
Both the Na /K and the pH gradient vesicles were dehydrated ; 20 under high vacuum for 24 hours and then rehydrated. Control vesicles were kept at ~C for 24 hours. Pollowing drying and rehydration, the transmembrane potentials exhibited by these vesicles in the presence and absence of ionophores were compared to the transmembrane potentials generated by the controls, also in the presence and absence of ionophores. The results are shown in Figures 6 (pH) and 7 (Na /K ).
As can be seen from these figures, the transmembrane potentials exhibited by the vesicles which had been dehydrated and ~ then rehydrated are essentially identical to those exhibited by - 30 the controls. The only apparent difference is that in the case of the pH gradient vesicles, the transmembrane potentials for the dehydrated/rehydrated vesicles develop somewhat slower than the transmembrane potentials for the control vesicles.
The ability of the Na /K vesicles to accumulate adriamycin after dehydration and rehydration was tested in the presence and absence of the ionophore valinomycin, and compared with the "`` ~2~3~
accumulation exhibited by ehe control vesicles, i.e., the vesicles which had been stored at 4C for ~4 hours rather than being dehydrated for 24 hours. Sufficient adrlamycin was added to the vesicles' external medium to produce a final concentration of 0.2 moles adriamycin per mole of phospholipid.
The results of these tests are shown in Figure 8. As can be seen therein, the dehydrated/rehydrated vesicles accumulate adriamycin essentially at the same rate and to the same extent as the control vesicles.
Although not wishing to be bound by any particular theory of operation, one of the mechanisms involved ln the observed uptake of adriamycin in response to Na /K gradients may involve the pH
gradients which are automatically generated in response to such gradients due to the per~eability of liposome membranes to H+
ions. In accordance with this mechanism, adriamycin passes through the membrane in an uncharged state, with its internal and external concentrations being a function of the internal and external H ion concentrations, the internal concentration being high when the lnternal H concentration is high, and vice versa.
In sum, this example demonstrates that delayed loading of vesicles can be accomplished through the combination of concentration gradients and the dehydration/rehydration process.
Example 7 Dehydra~ion of Liposomes Having Mul~ple Lipid Layers Without_Prior Freezin~ and Without the Use of a Protective Sugar This example illustrates that liposomes having multiple lipid layers will retain a substantial portion of their internal contents during dehydration and subsequent rehydration, even without the use of a protective sugar, provided that the dehydration is performed without prior freezing of the liposomes and provided that the dehydration is performed to an end point where there is sufficient water left in the preparation so that a substantial portion of the membranes retain their integrity upon rehydration.
~8~
The experiments were performed using the following types of liposomes, all of which include multiple lipid layers: multila-mellar liposomes (MLVs), stable plurilamellar liposomes (SPLVs), and monophasic vesicles (MPVs). A detailed description of suit-able techniques for producing SPLVs and MPVs appears in commonly assigned U.S. Patents Nos. 4,522,803 and 4,588,578. Descriptions of methods for preparing MLVs can be found throughout the litera-ture, including, for example, the Liposome text (Marc J. Ostro, ed., 1983) and the Szoka, Jr., et al. reference (Ann. Ref. Bio-phys. Bioengr., 1980), referred to above.
The materials and experimental protocol used were as fol-lows. All three types of liposomes were made with egg phosphati-dylcholine tEPC) obtained from Sigma Chemical Company and with Hepes buffer with and without trehalose (i.e., 20 mM Hepes, 150 mM NaCl, pH 7.4 -- Buffer O; or 20 mM Hepes, 150 mM NaCl, 250 mM
trehalose, pH 7.4 -- Buffer 250). CrO4 (New ~ngland Nuclear) in normal saline was used as the tracer. 0.01 ml of the tracer produced a cpm level of approximately 500,000.
For each of the three types of liposomes, the EPC was dis-solved in CHC13 (100 mg/ml) and 3.14 ml of the resulting solu-tion was deposited on the sides of a glass, round bottom flask using a Rotovap evaporator. To make SPLVs, the lipid was redis-solved in ether (10 ml) to which was added 0.5 ml of either Buf-fer O or Buffer 250 which included 0.01 ml of the tracer solution.
The ether was blown off under a stream of nitrogen while sonicat-ing in a bath sonicator. 4.5 ml of Buffer O or Buffer 250 was then added, producing a final lipid concentration of 62.8 mg/ml.
To make MPVs, the lipid was redissolved in 100% ethanol (10 ml) to which was added 0.5 ml of either Buffer O or Buffer 250 which included 0.01 ml of the tracer solution. The ethanol was evaporated off at 55-60C using a Rotovap evaporator. 4.5 ml of * Trade Mark ~2836~L
-~4-Bufter O or Buffer 250 was then added, producing a final lipid concentration of 62.8 mg/ml.
MLVs were made by adding 5.0 ml of Buffer O or Buffer 250 to the round bottom flask and then vortexing the samples with glass beads for approximately 5 minuees. The buffers included 0.0~ ml of the tracer solueion. As with the SPLVs and the MPVs, the final lipid concentration was 62.8 mg/ml.
Once all six liposomes samples had been prepared (on~ with and one without trehalose for each of the three types of liposomes), they were removed from the round bottom flasks by vortexlng for approximately 5 minutes, and each sample was placed in a dlalysis bag made of Thomas 12,000 M.W. dialysis tubing.
The radioactivity of each bag was counted and the bags were then dialyzed against 500 ml of Buffer O or Buffer 250, as appropriate, until a stable count was reached indicating that the tracer had been removed from ehe external medium surrounding the liposomes.
Dialysls for approxlmately 24 hours was found sufficient to reach a stable count.
Without prior freezing, 1.0 milliliter of each sample was drled for 24 hours in a 10 ml Kimex tube at room temperature under high vacuum using a Virtis Freeze Drier (Gardiner, N.Y.). As the results presentet belo~ for the liposome preparations which did not include trehalose show, dehydration for this period of time and under these conditions resulted in dehydrated preparaeions which lncluded sufficlent residual water so that a substantial portion of the liposome membranes retained their ineegrity upon rehydration even though a protective sugar was not used.
After dehydration, the lipo~omes were placed in 0.9 ml of distilled water and slo~ly rehydrated with gentle swirling or vortexing, as neces-qary.
The rehydrated liposo~es were transferred to dialysis bags of the type describet above and their ratioactivity measured. The bags were then dialyzed agalnst Buffer O or Buffer 250, as appropriate, for approximately 18 hours and their radioactivity measured again. The a~ount of radioactlvlty retained by the liposomes after dialysis was used as a measure of the amount of * Trade Mark ~ ~%~33~ 014 internal contents which the liposomes were able to retaln through the dehydratlon/rehydraLion process. As a control, 1.0 mllllliter or each sample was placed in a 10 ml Rimex tube, held at room temperature without drying for 24 hours, placed in a dialysis bag, measured for radioactivlty, dialyzed against the appropriate buffer, and then remeasured for radloactivity.
The results of these experiments were as follows, where the percentages given are the counts per minute after dialysls relative to the counts per minute before dialysis and where the numbers in parentheses are the control values:
O_Buffer 250 Buffer MLVs 91.9~ (87.7%) 84.4~ (100.1~) SPLVs 85.1~ (82.7%) 84.3% (94.2~) MPVs 85.5% (90.1~) 75.9% (93.2%) As shown by these results, well over 80~ of the lnternal coneents of each of the three types of liposo~es was retained after the dehydration/rehydration process without ~he use of any protective sugars. Moreover, addlng trehalose to these types of liposomes somewhat decreased, rather than increased, the amount of internal contents retained in the liposomes after the dehydration/rehydration process.
Dehydratlon of Liposo~es Without The Use of a Protectlve Suvar . . _ ~
Quantlflcation of Preferred Residual Water Levels This example illustrates that when a llposome preparation is dehydrated without the use of a proeective sugar, at least about 2%, and preferably between about 2% and about 5~, of the original water in the preparation should remain in the preparation at the end of the dehydration process so that the liposomes will retain a substantial portion of their internal contents upon rehydration.
The experiments were perfor~ed using stable plurila~ellar liposomes (SPLVs) and freeze and thaw multilamellar vesicles (FAT~LVs), both of which include multiple lipid ~ayers. A
detailed description of suitable techniques for producing SPLVs appears in U.S. Patent No. 4,522,803, referred to -26 ~3~
above. See also, Grunner et al., (1985) Biochemistry, 24:2833.
A description of techniques for producing FATMLVs can be found in copending and commonly assigned Canadian Patent Application No. 520,029.
The materials and experimental protocol used were as fol-lows. Egg phosphatidylcholine (99%) was purchased from Avanti Polar Lipids, Inc. (Birmingham, Alabama). [ C]inulin and tri-tiated water were obtained from New England Nuclear (Boston, Massachusetts). Tritiated water and [ C]inulin were counted in a Beckman LS6800 liquid scintillation counter set for 2 channel operation. All data were corrected for isotope counting effici-ency and channel spillover.
SPLVs were prepared by adding 400 umoles of egg PC in chloro-form to a 100 ml round bottom flask. Bulk solvent was removed by evaporation for approximately 2 minutes using a Rotovap evapora-tor; the lipid was not taken to dryness. Ten milliliters of an-hydrous diethyl ether (J.T. Baker Chemical Co., Phillipsburg, New Jersey) was added to the flask to redissolve the lipid. To this solution was added 0.3 ml of equimolar 145 mM NaCl/KCl with 20 mM
HEPES (pH 7.4) containing [ C]inulin (16.67 uCi/ml, specific ac-tivity 2.4 mCi/g) and unlabeled inulin to bring the final inulin concentration to 1.42 umol inulin/0.3 ml buffer. The samples were sonicated for 1 minute for dispersion and then dried with N2 while sonicating until the odor of ether was no longer detectable. The lipid was resuspended in 10 ml of buffer and transferred to a 30 ml Corex tube.
Unentrapped [14C]inulin was removed by 4 washlcentrifugation cycles, the centrifugation being conducted for 30 minutes at 12,100 x g in a Beckman J2-21 centrifuge with a JA-20 rotor. The first wash was performed with 10 ml, and subsequent washes with 20 ml, of buffer.
After decanting the final wash supernatant, the vesicle pel-let was resuspended with 5 ml of buffer containing tritiated water (2.5 uCi/ml, specific activity 1 mCi/g). The lipld .
* Trade Mark concen~ration of this preparation was determined by dividing the amoune of lipid used (400 umol) by the measured volume of the preparation. For the SPLV Liposomes, the average volume was 6.01 + 0.04 ml, glving an average lipld concentration of 6.65 x 10 5 moles lipid/m]
The radioactivity of the tritiated buffer used to resuspend the vesicles was measured and found to be 5.55 x 106 dpm/ml (dpm =
disintegrations per minute). To be able to calculate residual water values ln the dehydrated preparations in terms of moles of water per mole of lipid (see below), this dpm/ml value was converted to a moles H2OIdpm value by dividing the dpm/ml value by the conceneration of water in the buffer. For this purpose, the buffer was assumed to be pure water 90 thae the concentration of water was 5.55 x 10 2 moles H20/ml. The moles ~ 0/dpm value was thus calculated to be 1.00 x 10 8 moles H2O/dpm.
After resuspension in the tritiated buffer, the preparation was held for a period of at least 30-60 minutes at room temperature prior to dehydra~ion to allow the tritiated water to equilibrate throughout the preparatlon.
FATMLVs were prepared by adding 400 umoles of ~gg PC ln chloroform to a 100 ml round bottom flask. Solvent was removed by rotary evaporation for 5 minute~, followed by 2 hours under high vacuum in a dessicator (see dehydration dlscussion below for a description of the specific equipment used).
The llpid was hytrated with 5 ml of equlmolar 145 mM NaCl/KCl and 20 mM Hepes (pH 7.4) containing [14C]inulin (I uCi/ml, speciflc activity 2.4 mCi/g) ant unlabeled inulln to bring the final lnulin concentration to 1.08 mM.
The mixture was dlspersed by vortexing and aliquots were transferred to 1.8 ml Nunc cryo tubes (Nunc, Denmark). The samples were successively fro~en in liquid nitrogen and thawed in war~ water five times. The content~ were pooled, mixed and transferred to a 30 ml Corex tube.
Unencapsulated [14C]inulin was removed by 4 wash/centrifugation cycles, usin~ 20 ml of buffer for each wash. The centrifugations were performed ln the manner described above for SPLVs.
* Trade Mark 12~33G04 After decanting the final wash supernatant, the vesicle pellet was resuspended with 5 ml of the qame tritiated waeer buffer used to resuspend the SPLVs. The final preparation was held for a period of at least 30-60 minutes prior to dehydration to allow the tritiated water to equilibrate throughout the preparation. As with the SPLV experiments, the lipid concentration of the preparation was determined by dividing the amount of lipid used (400 umol) by the measured volume of the preparation. In this case, the average volume was 7.13 + 0.06 ml, giving an average lipid concentration of 5.60 x 10 5 moles lipid/ml.
The radioactivity due to tritiated water of aliquots of the resuspended SPLVs and FATMLYs was measured and an average value of
4.18 x 10 + 1.49 x 105 dpm/ml was obtained for the SPLV
suspensions and an average value of 3.60 x 10 ~ 1.41 x 10 dpm/ml was obtalned for the FATMLV suspensio~s. Using the 1.00 x 10 8 moles H20/dpm value measured for the buffer without vesicles, these radioactivity values were converted to water concentrations for the 5PLV and FAT~LV suspensions. Specifically, a waeer concentraeion of 4.18 x 10 2 moles H20/ml was calculated for the SPLV suspension, and a water concentration of 3.60 x 10 moles H20/ml was calculated for the FATMLV suspension. As described below, these values along with the lipid concentrations given above were uset to calculate the residual water values in the dehydrated preparatlon in term~ of moles of water per mole of lipid.
In addition to measuring the radioactivlty of the resuspended preparations due ~o tritiated water, ehe radioactivi~y due to [14C]inulin wa6 also measured.
The preparations were then dehydrated. Specifically, multiple samples were pipetted into 30 ml Corex tubes (approximately 1 ml of suspension per tube), and the weight of the tube plus suspension recorded. The samples were then dried at room temperature under high vacuu~ with a model D4A Maxima Vacuum Pump (Flsher Scientlfic, Fairla~n, N.J.) having an ultimate * Trade Mark 2~33~
partial pressure rating of 3 x 10 4 Torr and a displacement capacity of 127 liters/minute.
The dehydration was carried out for periods of time up to 48 hours, with samples being removed at various points in time and rehydrated with distilled water to their pre-dehydration weight.
The vesicles were dispersed by gentle vortexing and the sample was held for approximately 15-30 minutes to allow the tritiated water remaining in the sample after the dehydration process to equilibrate throughout the preparation.
An aliquot was then removed from the sample and its radioactivity per ml due to tritiated water was measured.
Percent residual water levels for the dehydrated samples, i.e., the percentage of the original water remaining in the sample after the dehydration process, were then calculated by simply dividing the measured radioactivity levels after rehydration by the average pre-dehydration values given above, i.8., by 4.18 x 106 dpm/ml for SPLVs and 3.60 x 10 dpm/ml for FAT~LVs.
The percent residual water values were convarted to moles of water per mole of lipid in the dehydrated preparation by multiplying the percent values by the water concentrations given above, i.e., by 4.18 x 10 2 moles H20/ml for SPLVs and by 3.60 x moles H20/ml for FATMLVs, and dividing by the lipid concentrations, i.e., by 6.65 x 10 5 moles lipid/ml for SPLVs and S.60 x 10 5 moles lipid/ml for FATMLVs. For example, the calculated values obtained for the integer percentages between l and 6 percent were:
residual water water/lipid ratio SPLV FATMLV
6.0 37.7/1 38.6/
suspensions and an average value of 3.60 x 10 ~ 1.41 x 10 dpm/ml was obtalned for the FATMLV suspensio~s. Using the 1.00 x 10 8 moles H20/dpm value measured for the buffer without vesicles, these radioactivity values were converted to water concentrations for the 5PLV and FAT~LV suspensions. Specifically, a waeer concentraeion of 4.18 x 10 2 moles H20/ml was calculated for the SPLV suspension, and a water concentration of 3.60 x 10 moles H20/ml was calculated for the FATMLV suspension. As described below, these values along with the lipid concentrations given above were uset to calculate the residual water values in the dehydrated preparatlon in term~ of moles of water per mole of lipid.
In addition to measuring the radioactivlty of the resuspended preparations due ~o tritiated water, ehe radioactivi~y due to [14C]inulin wa6 also measured.
The preparations were then dehydrated. Specifically, multiple samples were pipetted into 30 ml Corex tubes (approximately 1 ml of suspension per tube), and the weight of the tube plus suspension recorded. The samples were then dried at room temperature under high vacuu~ with a model D4A Maxima Vacuum Pump (Flsher Scientlfic, Fairla~n, N.J.) having an ultimate * Trade Mark 2~33~
partial pressure rating of 3 x 10 4 Torr and a displacement capacity of 127 liters/minute.
The dehydration was carried out for periods of time up to 48 hours, with samples being removed at various points in time and rehydrated with distilled water to their pre-dehydration weight.
The vesicles were dispersed by gentle vortexing and the sample was held for approximately 15-30 minutes to allow the tritiated water remaining in the sample after the dehydration process to equilibrate throughout the preparation.
An aliquot was then removed from the sample and its radioactivity per ml due to tritiated water was measured.
Percent residual water levels for the dehydrated samples, i.e., the percentage of the original water remaining in the sample after the dehydration process, were then calculated by simply dividing the measured radioactivity levels after rehydration by the average pre-dehydration values given above, i.8., by 4.18 x 106 dpm/ml for SPLVs and 3.60 x 10 dpm/ml for FAT~LVs.
The percent residual water values were convarted to moles of water per mole of lipid in the dehydrated preparation by multiplying the percent values by the water concentrations given above, i.e., by 4.18 x 10 2 moles H20/ml for SPLVs and by 3.60 x moles H20/ml for FATMLVs, and dividing by the lipid concentrations, i.e., by 6.65 x 10 5 moles lipid/ml for SPLVs and S.60 x 10 5 moles lipid/ml for FATMLVs. For example, the calculated values obtained for the integer percentages between l and 6 percent were:
residual water water/lipid ratio SPLV FATMLV
6.0 37.7/1 38.6/
5.0 31.4/1 32.1/1 4.0 25.2/1 25.7/1 3.0 18.9/1 19.3/1 2.0 12.6/1 12.9/1 1.0 6.3/l 6.4/1 After the radioactivity of the rehydrated preparation due to tritiated water had been measured, inulin retention was determined by first sub~ecting the rehydrated sample to 3 wash/centrifugation ;36~)4 cycles using 10 milliliters of buffer per wash. The centrifugation was performed for 25 minutes at 12,100 x g using the equipment described above. The vesicles in the final wash pellet were resuspended to their original weight with buffer and assayed for [14C]inulin. Percent inulin retained values were calculated by dividing the post-rehydration radioactivity values by the pre-dehydration values.
The results of these experiments are shown graphically in Figure 9. As shown therein, the percent inulin retained values remain relatively constant down to a residual water level of about 5%, i.e., a moles of water/moles of lipid value for the dehydrated preparation on the order of 35. Thereafter, increasingly greater amounts of inulin loss are seen with reduced residual water levels, with losses on the order of 30-40% and more being seen once the residual water level drops below about 2.0%, i.e., a moles of water/moles of lipid value for the dehydrated preparation on the order of 12.
Since for long-term storage, it is in general desirable to have a minimal amount of water in the preparation, these results demonstrate that to achieve this goal and still have reasonably low levels of vesicle rupture, the residual water level in the dehydrated preparation should preferably be kept between about 2%
and about 5%, or in terms of moles of water per mole of lipid, between about 12 moles H20/mole lipid and about 35 moles H20/mole 25 lipid.
Example 9 Dehydration of Liposomes Without The Use of ~ Protective Sugar:
Effects of Vesicle Type, Lipid Type and Lipid Concentration This example illustrates the effects of vesicle type, lipid type, and lipid concentration on the dehydration of liposomes without a protective sugar.
SPLVs and FATMLVs were prepared as described in Example 8 with the following changes: 1) both egg PC and soy PC (Avanti Polar Lipids, Birmingham, Alabama) were used; 2) the starting ' ~ -31- ~2836~
amount of lipid was either 400 umoles, as in Example 8, or 15 umoles; 3) 1.0 uCi/ml tritiated water was added to the buffer, rather than 2.5 uCitml tritiated water; and 4) in the case of SPLVs, inulin and radioactive inulin were added both in accord-ance with the procedures of Example 8 and by adding [14C]inulin (3.34 uCi/ml, specific activity 2.4 mCi/g) and unlabelled inulin to bring the final inulin concentration to 1.08 umol inulin/0.3 ml buffer. With regard to this last change, it was found that the measured values of retained inulin were indistinguishable for the two radioactive inulin preparations.
MPVs were prepared following the procedures of U.S. Patent No. 4,588,578, referred to above in Example 7. Specifically, either 15 or 400 umoles of egg PC or soy PC in chloroform were added to a 100 ml round bottom flask. The solvent was removed by rotary evaporation for 5-10 minutes, followed by 30 minutes under high vacuum using the equipment described in Example 8.
Five milliliters of 100% ethanol was added to the flask to re solubilize the lipids. To this solution was added 0.30 ml of equimolar 145 mM NaCl/KCl with 20 mM HEPES (pH 7.4) containing [1 C]inulin (16.67 uCi/ml, specific activity 2.4 mCi/g) and un-labeled inulin to bring the final inulin concentration to 1.42 umol inulin/0.3 ml buffer. The contents of the flask were mixed by vortexing, and the mixture was dried to a thin film by rotary evaporation for 5-10 minutes, followed by 30 minutes under high vacuum, again using the equipment of Example 8. The lipid was resuspended in 5 ml of buffer and transferred to a 30 ml Corex tube.
Unincorporated [ 4C~inulin was removed by 4 wash/centrifuga-tion cycles, using 20 milliliters of buffer for each wash. Cen-trifugation was performed for 30 minutes as described in Example 8. After decanting the final wash supernatant, the vesicle pel-let was resuspended with 5 ml of buffer containing tritiated water (1.0 uCi/ml, specific activity 1 mCi/g). The preparation was then held for a period of at least 30-60 minutes prior to dehydration to allow for equilibration of the tritiated water throughout the preparation.
* Trade Mark 83~
MLVs were prepared by adding either 15 or 400 umoles of egg PC or soy PC in chloroform ~o a 100 ml round bottom flask.
Solvent was removed by rotary evaporation for 5 minutes, followed by 2 hours under high vacuum, using the equipment of Example 8.
The lipid was hydrated wlth 5 ml of equimolar 145 mM NaCl/KCl with 20 mM HFPES (pH 7.4) containing [ C]inulin ~1.0 uCi/ml, specific activlty 2.4 mCi/g) and unlabeled inulin to bring the final inulin concentration to 1.08 ~M. The lipid was dispersed by vortexing and the suspension was allowed to swell for 2 hours.
Unsequestered [ C~inulin was removed and tritiated water ~as added following the procedures deccribed above for ~PV5.
One milliliter sample~ of the sixteen preparations ta hlgh concentration EPC, a low ~oncentration EPC, a hlgh concentrat:ion SPC, and a low concentration SPC for SPLVs, FATMIVs, MPYs and MLVs) were placed in 30 ml Corex tubes and dried ln a dessicator for 2 days at roo~ ~emperature under high vacuum uslng the vacuum pump described in Example 8. Another set of samples were lyophilized. Specifically, 1 ml samples were frozen using the shell freezing technique in 30 ml Corex tubes and then drled *
overnight in a model FDX-1-84-D Flexi-dry lyophilization unit (FTS
Systems, Inc., Ston~ Ridge, New York). Control samples ~1 ~l in 30 ml Corex tubes) were coveret and left at room temperature for 2 days.
Percene inulin retention and percent residual water were deeermined followlng the procedures ant using the equipment descrlbed in Example 8. The results are shown in Table 6.
A comparison of the inulln retention values for ~he various preparations reveals that: 1) for~ulations having a high phospholipid concentration prlor to dehydration suffer less damage (i.e., less leakage of the internal contents of the liposomes) than formulatlons having a low phospholipid concentration; 2) egg PC vesicles generally suffer less damage than soy PC vesicles; and 3) MPVs generally suffer less damage than SPLVs and FATMLVs. In addition, the data shows that freezing of the preparation prior to dehydration (the "lyophilization" experiments) results in signlficantly more damage Co the veslcles than does dehydration * Trade Mark ``` ~ 33604 without prior freezing (the "vacuum dessication" experiments), irrespective of vesicle type, lipid type, or lipid concentration.
Although specific embodiments of the invention have been described and illustrated, it is to be understood that modifications can be made without departing from the invention's spirit and scope. For example, liposome preparation techniques other than those used in the examples can be used to prepare the ; liposomes which are to be dehydrated and then rehydrated.
Similarly, charged materials other than adriamycin can be loaded into liposomes using a transmembrane potential.
, ~36~
TABLE l Ability of Dehydrated Vesicles to Retain Adriamycin Adriamycin Content (nmoles/umole lipid) Before dehydration 197 Immediately after dehydration and rehydration 185 One hour after dehydration and rehydration 158 Two hours after dehydration and rehydration 145 ETVs were prepared using a solute solution containing adriamycin and 250 mM trehalose. The samples were dehydrated for 24 hours without prior freezing. The adriamycin content of the initial sample and the rehydrated vesicles was determined as described in Example 1.
Drying Time 22Na retained Residual water Sample (Hrs.) % %
~ Trehalose on both : sides of membrane (250 mM) 24 94 5.6 48 84 5.4 72 84 5.2 : Trehalose on outside of membrane ; (250 mM) 24 68 5.4 48 49 5.0 72 17 4.2 ~2133~
Influence of Vesicle Size on Ability to Retain Na Polycarbonate Vesicle mean % Na retained filter pore diameter (nm) following size (nm~ dehydration and : rehydration , 800 S00 80%
400 220, 500 84%
200 180, 375 87%
; 100 170 92%
112 88%
, Vesicles were prepared with varying mean diameters by extruding multilamellar vesicles through polycarbonate filters of appropriate diameters (see "Materials and Methods"). The samples all contained 250 mM trehalose and were dehydrated for 24 hours without prior freezing.
"` ~L2836(~4L
.
TABLE_4 Comparison of the Ability of Different Sugars To Stabilize Vesicles in the Anhydrous State Sugar tested (500 mM) % 22Na+ retained following dehydration and rehydration Trehalose 88%
Glucose 73%
Sucrose 86%
Maltose 76%
LactosP 66%
Large unilamellar vesicles were prepared in the presence of 500 mM
of each sugar, dehydrated for 24 hours without prior free~ing, and the amount of trapped Na retained upon rehydration determined as described in "Materials and Methods."
31~iO~
Ability of Streptomycin to Protect Vesicles During Dehydration-Rehydration : 3 H Inulin Retained ControlFreeze-Dried ;~ PBS plus 52 mM
~ streptomycin 92 31 : PBS plus 568 mM
streptomycin 94 86 _ _ Monophasic vesicles were prepared and washed in the presence and ~` absence of streptomycin, dehydrated under vacuum with prior freezing, and rehydrated as described in Example 5. The contrQl vesicles were stored at room temperature for the same periods of time as used for the freeze-drying process (24 hours).
~2~361)~
Inulin Retention as a Function of Vesicle Type, Lipid Type and Lipid Concentration Lipid Vacuum Concentration DessicationLyophilizationControl MPV
EPC (low) 47.0 + 0.527.1 + 3.1 86.6 + 6.1 EPC (high) 63.9 + 6.058.3 + 1.7 101.3 + 1.8 SPC (low) 41.0 + 3.529.2 + 5.3 71.7 + 10.1 SPC (high) 54.6 + 5.442.4 + 1.8 96.9 + 2.2 MLV
EPC (low) 44.6 + 14.740.7 + 24.6 N.D.
EPC (high) 62.0 + 3.855.4 + 5.8 99.8 + 2.1 SPC (low) 28.4 + 10~118.3 + 3.9 N.D.
SPC (high) 60.4 + 2.253.8 + 3.3 98.4 + 7.8 SPLV
EPC (low)31.3 + 0.6 17.0 + 3.8 69.3 + 7.5 EPC (high) 56.4 + 1.954.4 + 3.5 98.5 + 2.8 SPC (low) 37.2 + 2.924.6 + 0.2 87.6 + 1.0 SPC (high) 48.4 + 6.244.6 + 2.3 97.8 + 1.7 FATMLV
EPC (low)35.6 + 4.2 18.4 + 2.6 102.1 + 4.g EPC (high) 54.9 + 0.134.8 + 7.7 95.3 + 0.4 SPC (low) 24.6 + 12.224.4 + 1.6 89.8 + 11.4 SPC (high) 43.7 + 6.027.9 + 0.7 96.1 t 1 . 4 alues reported = % of original inulin retained in the preparation after dehydration and rehydration + S.D.
N.D. z Not determined.
Low lipid concentration = 3 umol lipid hydrated with 1 ml prior to dehydration.
High lipid concentration = 80 umol lipid hydrated with 1 ml prior to dehydration.
Drylng Time - Vacuum Dessication -- 2 days - Lyophilization -- 1 day (residual water levels after dehydration equaled approximately 2% or less for both procedures) Number of experiments per data point = 2; data corrected for blank, 2 channel spillover; EPC = Egg PC; SPC = Soy PC.
The results of these experiments are shown graphically in Figure 9. As shown therein, the percent inulin retained values remain relatively constant down to a residual water level of about 5%, i.e., a moles of water/moles of lipid value for the dehydrated preparation on the order of 35. Thereafter, increasingly greater amounts of inulin loss are seen with reduced residual water levels, with losses on the order of 30-40% and more being seen once the residual water level drops below about 2.0%, i.e., a moles of water/moles of lipid value for the dehydrated preparation on the order of 12.
Since for long-term storage, it is in general desirable to have a minimal amount of water in the preparation, these results demonstrate that to achieve this goal and still have reasonably low levels of vesicle rupture, the residual water level in the dehydrated preparation should preferably be kept between about 2%
and about 5%, or in terms of moles of water per mole of lipid, between about 12 moles H20/mole lipid and about 35 moles H20/mole 25 lipid.
Example 9 Dehydration of Liposomes Without The Use of ~ Protective Sugar:
Effects of Vesicle Type, Lipid Type and Lipid Concentration This example illustrates the effects of vesicle type, lipid type, and lipid concentration on the dehydration of liposomes without a protective sugar.
SPLVs and FATMLVs were prepared as described in Example 8 with the following changes: 1) both egg PC and soy PC (Avanti Polar Lipids, Birmingham, Alabama) were used; 2) the starting ' ~ -31- ~2836~
amount of lipid was either 400 umoles, as in Example 8, or 15 umoles; 3) 1.0 uCi/ml tritiated water was added to the buffer, rather than 2.5 uCitml tritiated water; and 4) in the case of SPLVs, inulin and radioactive inulin were added both in accord-ance with the procedures of Example 8 and by adding [14C]inulin (3.34 uCi/ml, specific activity 2.4 mCi/g) and unlabelled inulin to bring the final inulin concentration to 1.08 umol inulin/0.3 ml buffer. With regard to this last change, it was found that the measured values of retained inulin were indistinguishable for the two radioactive inulin preparations.
MPVs were prepared following the procedures of U.S. Patent No. 4,588,578, referred to above in Example 7. Specifically, either 15 or 400 umoles of egg PC or soy PC in chloroform were added to a 100 ml round bottom flask. The solvent was removed by rotary evaporation for 5-10 minutes, followed by 30 minutes under high vacuum using the equipment described in Example 8.
Five milliliters of 100% ethanol was added to the flask to re solubilize the lipids. To this solution was added 0.30 ml of equimolar 145 mM NaCl/KCl with 20 mM HEPES (pH 7.4) containing [1 C]inulin (16.67 uCi/ml, specific activity 2.4 mCi/g) and un-labeled inulin to bring the final inulin concentration to 1.42 umol inulin/0.3 ml buffer. The contents of the flask were mixed by vortexing, and the mixture was dried to a thin film by rotary evaporation for 5-10 minutes, followed by 30 minutes under high vacuum, again using the equipment of Example 8. The lipid was resuspended in 5 ml of buffer and transferred to a 30 ml Corex tube.
Unincorporated [ 4C~inulin was removed by 4 wash/centrifuga-tion cycles, using 20 milliliters of buffer for each wash. Cen-trifugation was performed for 30 minutes as described in Example 8. After decanting the final wash supernatant, the vesicle pel-let was resuspended with 5 ml of buffer containing tritiated water (1.0 uCi/ml, specific activity 1 mCi/g). The preparation was then held for a period of at least 30-60 minutes prior to dehydration to allow for equilibration of the tritiated water throughout the preparation.
* Trade Mark 83~
MLVs were prepared by adding either 15 or 400 umoles of egg PC or soy PC in chloroform ~o a 100 ml round bottom flask.
Solvent was removed by rotary evaporation for 5 minutes, followed by 2 hours under high vacuum, using the equipment of Example 8.
The lipid was hydrated wlth 5 ml of equimolar 145 mM NaCl/KCl with 20 mM HFPES (pH 7.4) containing [ C]inulin ~1.0 uCi/ml, specific activlty 2.4 mCi/g) and unlabeled inulin to bring the final inulin concentration to 1.08 ~M. The lipid was dispersed by vortexing and the suspension was allowed to swell for 2 hours.
Unsequestered [ C~inulin was removed and tritiated water ~as added following the procedures deccribed above for ~PV5.
One milliliter sample~ of the sixteen preparations ta hlgh concentration EPC, a low ~oncentration EPC, a hlgh concentrat:ion SPC, and a low concentration SPC for SPLVs, FATMIVs, MPYs and MLVs) were placed in 30 ml Corex tubes and dried ln a dessicator for 2 days at roo~ ~emperature under high vacuum uslng the vacuum pump described in Example 8. Another set of samples were lyophilized. Specifically, 1 ml samples were frozen using the shell freezing technique in 30 ml Corex tubes and then drled *
overnight in a model FDX-1-84-D Flexi-dry lyophilization unit (FTS
Systems, Inc., Ston~ Ridge, New York). Control samples ~1 ~l in 30 ml Corex tubes) were coveret and left at room temperature for 2 days.
Percene inulin retention and percent residual water were deeermined followlng the procedures ant using the equipment descrlbed in Example 8. The results are shown in Table 6.
A comparison of the inulln retention values for ~he various preparations reveals that: 1) for~ulations having a high phospholipid concentration prlor to dehydration suffer less damage (i.e., less leakage of the internal contents of the liposomes) than formulatlons having a low phospholipid concentration; 2) egg PC vesicles generally suffer less damage than soy PC vesicles; and 3) MPVs generally suffer less damage than SPLVs and FATMLVs. In addition, the data shows that freezing of the preparation prior to dehydration (the "lyophilization" experiments) results in signlficantly more damage Co the veslcles than does dehydration * Trade Mark ``` ~ 33604 without prior freezing (the "vacuum dessication" experiments), irrespective of vesicle type, lipid type, or lipid concentration.
Although specific embodiments of the invention have been described and illustrated, it is to be understood that modifications can be made without departing from the invention's spirit and scope. For example, liposome preparation techniques other than those used in the examples can be used to prepare the ; liposomes which are to be dehydrated and then rehydrated.
Similarly, charged materials other than adriamycin can be loaded into liposomes using a transmembrane potential.
, ~36~
TABLE l Ability of Dehydrated Vesicles to Retain Adriamycin Adriamycin Content (nmoles/umole lipid) Before dehydration 197 Immediately after dehydration and rehydration 185 One hour after dehydration and rehydration 158 Two hours after dehydration and rehydration 145 ETVs were prepared using a solute solution containing adriamycin and 250 mM trehalose. The samples were dehydrated for 24 hours without prior freezing. The adriamycin content of the initial sample and the rehydrated vesicles was determined as described in Example 1.
Drying Time 22Na retained Residual water Sample (Hrs.) % %
~ Trehalose on both : sides of membrane (250 mM) 24 94 5.6 48 84 5.4 72 84 5.2 : Trehalose on outside of membrane ; (250 mM) 24 68 5.4 48 49 5.0 72 17 4.2 ~2133~
Influence of Vesicle Size on Ability to Retain Na Polycarbonate Vesicle mean % Na retained filter pore diameter (nm) following size (nm~ dehydration and : rehydration , 800 S00 80%
400 220, 500 84%
200 180, 375 87%
; 100 170 92%
112 88%
, Vesicles were prepared with varying mean diameters by extruding multilamellar vesicles through polycarbonate filters of appropriate diameters (see "Materials and Methods"). The samples all contained 250 mM trehalose and were dehydrated for 24 hours without prior freezing.
"` ~L2836(~4L
.
TABLE_4 Comparison of the Ability of Different Sugars To Stabilize Vesicles in the Anhydrous State Sugar tested (500 mM) % 22Na+ retained following dehydration and rehydration Trehalose 88%
Glucose 73%
Sucrose 86%
Maltose 76%
LactosP 66%
Large unilamellar vesicles were prepared in the presence of 500 mM
of each sugar, dehydrated for 24 hours without prior free~ing, and the amount of trapped Na retained upon rehydration determined as described in "Materials and Methods."
31~iO~
Ability of Streptomycin to Protect Vesicles During Dehydration-Rehydration : 3 H Inulin Retained ControlFreeze-Dried ;~ PBS plus 52 mM
~ streptomycin 92 31 : PBS plus 568 mM
streptomycin 94 86 _ _ Monophasic vesicles were prepared and washed in the presence and ~` absence of streptomycin, dehydrated under vacuum with prior freezing, and rehydrated as described in Example 5. The contrQl vesicles were stored at room temperature for the same periods of time as used for the freeze-drying process (24 hours).
~2~361)~
Inulin Retention as a Function of Vesicle Type, Lipid Type and Lipid Concentration Lipid Vacuum Concentration DessicationLyophilizationControl MPV
EPC (low) 47.0 + 0.527.1 + 3.1 86.6 + 6.1 EPC (high) 63.9 + 6.058.3 + 1.7 101.3 + 1.8 SPC (low) 41.0 + 3.529.2 + 5.3 71.7 + 10.1 SPC (high) 54.6 + 5.442.4 + 1.8 96.9 + 2.2 MLV
EPC (low) 44.6 + 14.740.7 + 24.6 N.D.
EPC (high) 62.0 + 3.855.4 + 5.8 99.8 + 2.1 SPC (low) 28.4 + 10~118.3 + 3.9 N.D.
SPC (high) 60.4 + 2.253.8 + 3.3 98.4 + 7.8 SPLV
EPC (low)31.3 + 0.6 17.0 + 3.8 69.3 + 7.5 EPC (high) 56.4 + 1.954.4 + 3.5 98.5 + 2.8 SPC (low) 37.2 + 2.924.6 + 0.2 87.6 + 1.0 SPC (high) 48.4 + 6.244.6 + 2.3 97.8 + 1.7 FATMLV
EPC (low)35.6 + 4.2 18.4 + 2.6 102.1 + 4.g EPC (high) 54.9 + 0.134.8 + 7.7 95.3 + 0.4 SPC (low) 24.6 + 12.224.4 + 1.6 89.8 + 11.4 SPC (high) 43.7 + 6.027.9 + 0.7 96.1 t 1 . 4 alues reported = % of original inulin retained in the preparation after dehydration and rehydration + S.D.
N.D. z Not determined.
Low lipid concentration = 3 umol lipid hydrated with 1 ml prior to dehydration.
High lipid concentration = 80 umol lipid hydrated with 1 ml prior to dehydration.
Drylng Time - Vacuum Dessication -- 2 days - Lyophilization -- 1 day (residual water levels after dehydration equaled approximately 2% or less for both procedures) Number of experiments per data point = 2; data corrected for blank, 2 channel spillover; EPC = Egg PC; SPC = Soy PC.
Claims (19)
1. A method for dehydrating liposomes comprising the steps of preparing a liposome preparation composed of liposomes which have multiple lipid layers and removing water from the preparation without prior freezing of the preparation, said water being removed to an end point which results in sufficient water being left in the preparation so that the integrity of a substantial portion of the multiple lipid layers is retained upon rehydration.
2. The method of claim 1 wherein the amount of water left in the preparation is at least about 2 percent of the water present in the preparation prior to dehydration.
3. The method of claim 1 wherein the amount of water left in the preparation is between about 2 percent and about 5 percent of the water present in the preparation prior to dehydration.
4. The method of claim 1 wherein the amount of water left in the preparation is at least about 12 moles of water per mole of lipid.
5. The method of claim 1 wherein the amount of water left in the preparation is between about 12 and about 35 moles of water per mole of lipid.
6. Dehydrated liposomes prepared in accordance with the method of claim 1, 2 or 3.
7. Dehydrated liposomes prepared in accordance with the method of claim 4 or 5.
8. A dehydrated liposome preparation comprising:
a) liposomes which have multiple lipid layers; and b) a sufficient amount of water to protect the integrity of a substantial portion of the multiple lipid layers upon rehyd-ration of the preparation.
a) liposomes which have multiple lipid layers; and b) a sufficient amount of water to protect the integrity of a substantial portion of the multiple lipid layers upon rehyd-ration of the preparation.
9. The preparation of claim 8 wherein the preparation includes at least about 12 moles of water per mole of lipid.
10. The preparation of claim 8 wherein the preparation includes between about 12 and about 35 moles of water per mole of lipid.
11. The preparation of claim 8 wherein the preparation includes one or more protective sugars.
12. The preparation of claim 11 wherein the one or more protec-tive sugars are present at both the inside and outside surfaces of the liposome membranes.
13. The preparation of claim 11 wherein the one or more protec-tive sugars are disaccharide sugars.
14. The preparation of claim 11 wherein the one or more protec-tive sugars are selected from the group consisting of trehalose, mal-tose, sucrose, glucose, lactose and dextran.
15. The preparation of claim 14 wherein the sugar is trehalose.
16. The preparation of claim 14 wherein the sugar is sucrose.
17. The preparation of claim 11 wherein the one or more protec-tive sugars are aminoglycosides.
18. The preparation of claim 17 wherein the sugar is streptomy-cin.
19. The preparation of claim 17 wherein the sugar is dihydro-streptomycin.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63880984A | 1984-08-08 | 1984-08-08 | |
US638,809 | 1984-08-08 | ||
US74916185A | 1985-06-26 | 1985-06-26 | |
US749,161 | 1985-06-26 | ||
US06759419 US4880635B1 (en) | 1984-08-08 | 1985-07-26 | Dehydrated liposomes |
US759,419 | 1985-07-26 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000488004A Division CA1270197A (en) | 1984-08-08 | 1985-08-02 | Dehydrated liposomes |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1283604C true CA1283604C (en) | 1991-04-30 |
Family
ID=27417628
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000488004A Expired - Lifetime CA1270197A (en) | 1984-08-08 | 1985-08-02 | Dehydrated liposomes |
CA000615683A Expired - Lifetime CA1283604C (en) | 1984-08-08 | 1990-03-23 | Dehydrated liposomes |
CA000615684A Expired - Lifetime CA1294548C (en) | 1984-08-08 | 1990-03-23 | Dehydrated liposomes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000488004A Expired - Lifetime CA1270197A (en) | 1984-08-08 | 1985-08-02 | Dehydrated liposomes |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000615684A Expired - Lifetime CA1294548C (en) | 1984-08-08 | 1990-03-23 | Dehydrated liposomes |
Country Status (12)
Country | Link |
---|---|
US (4) | US4880635B1 (en) |
EP (3) | EP0190315B2 (en) |
JP (3) | JPH0818973B2 (en) |
AT (2) | ATE149347T1 (en) |
CA (3) | CA1270197A (en) |
DE (3) | DE3588148T2 (en) |
ES (2) | ES8701516A1 (en) |
HK (1) | HK1007501A1 (en) |
IE (1) | IE68686B1 (en) |
IL (1) | IL76010A (en) |
PT (1) | PT80926B (en) |
WO (1) | WO1986001103A1 (en) |
Families Citing this family (265)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5736155A (en) * | 1984-08-08 | 1998-04-07 | The Liposome Company, Inc. | Encapsulation of antineoplastic agents in liposomes |
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
EP0208764A4 (en) * | 1985-01-11 | 1987-10-08 | Univ California | Method for preserving liposomes. |
US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
US5171578A (en) * | 1985-06-26 | 1992-12-15 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
US5059421A (en) * | 1985-07-26 | 1991-10-22 | The Liposome Company, Inc. | Preparation of targeted liposome systems of a defined size distribution |
US5041278A (en) * | 1985-10-15 | 1991-08-20 | The Liposome Company, Inc. | Alpha tocopherol-based vesicles |
GB8604983D0 (en) * | 1986-02-28 | 1986-04-09 | Biocompatibles Ltd | Protein preservation |
US5252263A (en) * | 1986-06-16 | 1993-10-12 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
US5204112A (en) * | 1986-06-16 | 1993-04-20 | The Liposome Company, Inc. | Induction of asymmetry in vesicles |
IE60901B1 (en) * | 1986-08-21 | 1994-08-24 | Vestar Inc | Improved treatment of systemic fungal infections with phospholipid particles encapsulating polyene antifungal antibiotics |
US5043107A (en) * | 1986-08-21 | 1991-08-27 | Vestar Research, Inc. | Preparation small unilamellar vesicles including polyene antifungal antibiotics |
US5755788A (en) * | 1987-02-19 | 1998-05-26 | Rutgers, The State University | Prosthesis and implants having liposomes bound thereto and methods of preparation |
US6406713B1 (en) | 1987-03-05 | 2002-06-18 | The Liposome Company, Inc. | Methods of preparing low-toxicity drug-lipid complexes |
US5616334A (en) * | 1987-03-05 | 1997-04-01 | The Liposome Company, Inc. | Low toxicity drug-lipid systems |
US4963297A (en) * | 1987-12-22 | 1990-10-16 | The Liposome Company, Inc. | Spontaneous vesticulation of multilamellar liposomes |
MX9203808A (en) * | 1987-03-05 | 1992-07-01 | Liposome Co Inc | HIGH DRUG CONTENT FORMULATIONS: LIPID, FROM LIPOSOMIC-ANTINEOPLASTIC AGENTS. |
US5811118A (en) * | 1987-05-22 | 1998-09-22 | The Liposome Company, Inc. | Methods of treatment using unilamellar liposomal arachidonic acid metabolite formulations |
US5082664A (en) * | 1987-05-22 | 1992-01-21 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
JP2780755B2 (en) * | 1987-05-22 | 1998-07-30 | ザ リポソーム カンパニー,インコーポレイテッド | Prostaglandin-lipid preparation |
US5262168A (en) * | 1987-05-22 | 1993-11-16 | The Liposome Company, Inc. | Prostaglandin-lipid formulations |
US5925375A (en) * | 1987-05-22 | 1999-07-20 | The Liposome Company, Inc. | Therapeutic use of multilamellar liposomal prostaglandin formulations |
GB8715238D0 (en) * | 1987-06-29 | 1987-08-05 | Quadrant Bioresources Ltd | Food process |
US5178875A (en) * | 1991-01-14 | 1993-01-12 | The Board Of Regents, The University Of Texas System | Liposomal-polyene preliposomal powder and method for its preparation |
US5830498A (en) * | 1987-10-16 | 1998-11-03 | Board Of Regents, The University Of Texas System | Liposomal-polyene preliposomal powder and method for its preparation |
MX9203804A (en) * | 1987-10-19 | 1992-07-01 | Liposome Co Inc | PHARMACEUTICAL SYSTEMS BASED ON TOCOPHEROL. |
AU598958B2 (en) | 1987-11-12 | 1990-07-05 | Vestar, Inc. | Improved amphotericin b liposome preparation |
US4946683A (en) * | 1987-11-18 | 1990-08-07 | Vestar, Inc. | Multiple step entrapment/loading procedure for preparing lipophilic drug-containing liposomes |
EP0319638A1 (en) * | 1987-12-08 | 1989-06-14 | Estee Lauder Inc. | Liposome containing cosmetic and pharmaceutical compositions and methods for utilizing such compositions |
US5948441A (en) * | 1988-03-07 | 1999-09-07 | The Liposome Company, Inc. | Method for size separation of particles |
EP0437479B1 (en) * | 1988-10-05 | 1994-06-22 | Vestar, Inc. | Method of making liposomes with improved stability during drying |
WO1991000289A2 (en) * | 1989-06-23 | 1991-01-10 | The Liposome Company, Inc. | Targeted liposomes and methods for liposome-protein coupling |
US5104661A (en) * | 1989-08-14 | 1992-04-14 | Technology Unlimited, Inc. | Reverse loading of liposomes |
US5228446A (en) * | 1989-12-22 | 1993-07-20 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5542935A (en) * | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5352435A (en) * | 1989-12-22 | 1994-10-04 | Unger Evan C | Ionophore containing liposomes for ultrasound imaging |
US5305757A (en) * | 1989-12-22 | 1994-04-26 | Unger Evan C | Gas filled liposomes and their use as ultrasonic contrast agents |
US5580575A (en) * | 1989-12-22 | 1996-12-03 | Imarx Pharmaceutical Corp. | Therapeutic drug delivery systems |
US5230882A (en) * | 1989-12-22 | 1993-07-27 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5088499A (en) * | 1989-12-22 | 1992-02-18 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5334381A (en) * | 1989-12-22 | 1994-08-02 | Unger Evan C | Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same |
US5776429A (en) * | 1989-12-22 | 1998-07-07 | Imarx Pharmaceutical Corp. | Method of preparing gas-filled microspheres using a lyophilized lipids |
US5469854A (en) * | 1989-12-22 | 1995-11-28 | Imarx Pharmaceutical Corp. | Methods of preparing gas-filled liposomes |
US5882678A (en) * | 1990-01-12 | 1999-03-16 | The Liposome Co, Inc. | Interdigitation-fusion liposomes containing arachidonic acid metabolites |
AU660288B2 (en) * | 1990-07-31 | 1995-06-22 | Transave, Inc. | Accumulation of amino acids and peptides into liposomes |
CA2047969A1 (en) * | 1990-08-17 | 1992-02-18 | Thomas D. Madden | Benzoporphyrin vesicles |
US5885260A (en) | 1991-05-30 | 1999-03-23 | Mehl, Sr.; Thomas L. | Freeze-dried liposome delivery system for application of skin treatment agents |
US5325860A (en) * | 1991-11-08 | 1994-07-05 | Mayo Foundation For Medical Education And Research | Ultrasonic and interventional catheter and method |
US6890555B1 (en) | 1992-02-05 | 2005-05-10 | Qlt, Inc. | Liposome compositions of porphyrin photosensitizers |
CA2087902C (en) * | 1992-02-05 | 2006-10-17 | Narendra Raghunathji Desai | Liposome compositions of porphyrin photosensitizers |
US6005100A (en) * | 1992-12-02 | 1999-12-21 | Kabushiki Kaisha Hayashibara Seitbutsu Kagaku Kenkyujo | Trehalose composition for prolonging product shelf life |
JP3168550B2 (en) * | 1992-12-02 | 2001-05-21 | 株式会社林原生物化学研究所 | Dehydrating agent, method for dehydrating hydrated material using the same, and dehydrated article obtained by the method |
JP3329554B2 (en) * | 1993-03-10 | 2002-09-30 | 千葉製粉株式会社 | Dried er |
AU6833994A (en) * | 1993-05-17 | 1994-12-12 | Liposome Company, Inc., The | Incorporation of taxol into liposomes and gels |
US5576016A (en) * | 1993-05-18 | 1996-11-19 | Pharmos Corporation | Solid fat nanoemulsions as drug delivery vehicles |
WO1994027580A1 (en) * | 1993-05-21 | 1994-12-08 | The Liposome Company, Inc. | Reduction of liposome-induced adverse physiological reactions |
US6004534A (en) * | 1993-07-23 | 1999-12-21 | Massachusetts Institute Of Technology | Targeted polymerized liposomes for improved drug delivery |
WO1995003035A1 (en) * | 1993-07-23 | 1995-02-02 | Massachusetts Institute Of Technology | Polymerized liposomes with enhanced stability for oral delivery |
GB9320668D0 (en) | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
JP3187622B2 (en) | 1993-10-07 | 2001-07-11 | カネボウ株式会社 | Liposome |
WO1995011670A1 (en) * | 1993-10-25 | 1995-05-04 | The Liposome Company, Inc. | Liposomal defensins |
WO1996009037A1 (en) * | 1994-09-23 | 1996-03-28 | The Liposome Company, Inc. | Method of producing a lyophilized liposome product |
US5820873A (en) * | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
US6387399B1 (en) | 1994-12-02 | 2002-05-14 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Microencapsulated bioactive agents and method of making |
US6071535A (en) * | 1996-01-31 | 2000-06-06 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
US6183774B1 (en) | 1996-01-31 | 2001-02-06 | Collaborative Laboratories, Inc. | Stabilizing vitamin A derivatives by encapsulation in lipid vesicles formed with alkylammonium fatty acid salts |
US5874105A (en) * | 1996-01-31 | 1999-02-23 | Collaborative Laboratories, Inc. | Lipid vesicles formed with alkylammonium fatty acid salts |
US6165442A (en) * | 1996-02-19 | 2000-12-26 | Nycomed Imaging As | Thermally stabilized ultrasound contrast agent |
US6117449A (en) * | 1996-03-22 | 2000-09-12 | Bio-Sphere Technology, Inc. | Method for inducing a systemic immune response to a hepatitis antigen |
US6015576A (en) * | 1997-08-29 | 2000-01-18 | Bio-Sphere Technology, Inc. | Method for inducing a systemic immune response to an antigen |
US6207185B1 (en) | 1996-03-22 | 2001-03-27 | Bio-Sphere Technology | Method for inducing a systemic immune response to an HIV antigen |
CZ310798A3 (en) * | 1996-03-28 | 1999-02-17 | Trustees Of Boston University | Method of attenuating activation of tyrosinase, pigmentation adjustment and matter identification, substance intensifying tyrosinase phosphorylation, substance attenuating tyrosinase phosphorylation, use of peptide and use of dna |
CA2202103C (en) * | 1996-04-11 | 2007-01-09 | Toshiaki Tagawa | Method for preparing closed vesicles |
US6093816A (en) * | 1996-06-27 | 2000-07-25 | Isis Pharmaceuticals, Inc. | Cationic lipids |
DE19639811A1 (en) * | 1996-09-27 | 1998-04-02 | Artur Herzog Dr Mesmer | Use of a liposome solution to enhance the effectiveness and / or decrease the toxicity of drugs |
US5837282A (en) * | 1996-10-30 | 1998-11-17 | University Of British Columbia | Ionophore-mediated liposome loading |
US5935572A (en) * | 1997-01-10 | 1999-08-10 | Collaborative Laboratories, Inc. | Composition containing protease separate from glycosidase for removing nits in treating lice infestation |
US6060082A (en) | 1997-04-18 | 2000-05-09 | Massachusetts Institute Of Technology | Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery |
US6046166A (en) * | 1997-09-29 | 2000-04-04 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6518412B1 (en) | 1997-09-29 | 2003-02-11 | Jean-Louis Dasseux | Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6004925A (en) * | 1997-09-29 | 1999-12-21 | J. L. Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6037323A (en) | 1997-09-29 | 2000-03-14 | Jean-Louis Dasseux | Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders |
US6287590B1 (en) | 1997-10-02 | 2001-09-11 | Esperion Therapeutics, Inc. | Peptide/lipid complex formation by co-lyophilization |
US6734171B1 (en) | 1997-10-10 | 2004-05-11 | Inex Pharmaceuticals Corp. | Methods for encapsulating nucleic acids in lipid bilayers |
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
IL138672A0 (en) * | 1998-03-31 | 2001-10-31 | Yissum Res Dev Co | Liposomal bupivacaine compositions and methods of preparation |
US20010016346A1 (en) * | 1998-06-09 | 2001-08-23 | Joseph P. Noel | Pedtidyl-prolyl cis-trans isomerase inhibitors and uses therefore |
GB9813100D0 (en) * | 1998-06-18 | 1998-08-19 | Secr Defence | Method of forming liposomes |
CN1342075A (en) | 1999-03-11 | 2002-03-27 | 藤泽药品工业株式会社 | Liposome preparations |
US6613352B2 (en) | 1999-04-13 | 2003-09-02 | Universite De Montreal | Low-rigidity liposomal formulation |
CA2375532A1 (en) * | 1999-06-23 | 2000-12-28 | Cornell Research Foundation, Inc. | Dehydration/rehydration of marked liposomes on a test device |
GB9916316D0 (en) * | 1999-07-12 | 1999-09-15 | Quadrant Holdings Cambridge | Dry powder compositions |
EP1196144B1 (en) * | 1999-07-16 | 2004-09-22 | Alza Corporation | A liposome composition having resistance to freeze/thaw damage |
BR0015053A (en) * | 1999-10-18 | 2002-07-02 | Fujisawa Pharmaceutical Co | Method for producing a liposome preparation and liposome preparation |
US6710038B1 (en) | 1999-12-14 | 2004-03-23 | Kibun Food Chemifa Co., Ltd. | Emulsification method using propylene glycol hyaluronate |
WO2001056548A2 (en) * | 2000-02-04 | 2001-08-09 | Lipoxen Technologies Limited | Liposomes composition produced by a dehydration-rehydration process |
US8178150B2 (en) | 2000-02-22 | 2012-05-15 | Suzanne Jaffe Stillman | Water containing soluble fiber |
US7115297B2 (en) * | 2000-02-22 | 2006-10-03 | Suzanne Jaffe Stillman | Nutritionally fortified liquid composition with added value delivery systems/elements/additives |
US7892586B2 (en) | 2001-02-22 | 2011-02-22 | Suzanne Jaffe Stillman | Water containing soluble fiber |
JP2001316297A (en) * | 2000-02-23 | 2001-11-13 | Kaken Pharmaceut Co Ltd | Gene-embedded ribosome preparation and method for producing the same |
US8642051B2 (en) | 2000-03-21 | 2014-02-04 | Suzanne Jaffe Stillman | Method of hydration; infusion packet system(s), support member(s), delivery system(s), and method(s); with business model(s) and Method(s) |
IL151633A0 (en) | 2000-03-21 | 2003-04-10 | Stillman Suzanne Jaffe | Infusion packet with useful and decorative elements, support member delivery system and method |
US7309581B2 (en) * | 2000-11-01 | 2007-12-18 | Sysmex Corporation | Method of staining, detection and counting bacteria, and a diluent for bacterial stain |
AU2002219998B2 (en) * | 2000-12-01 | 2006-03-02 | Biomira, Inc. | Preparation of large liposomes by infusion into peg |
US7127357B1 (en) | 2000-12-08 | 2006-10-24 | The Salk Institute For Biological Studies | Crystal structure of WW domains and methods of use thereof |
US20070021360A1 (en) * | 2001-04-24 | 2007-01-25 | Nyce Jonathan W | Compositions, formulations and kit with anti-sense oligonucleotide and anti-inflammatory steroid and/or obiquinone for treatment of respiratory and lung disesase |
ES2607802T3 (en) | 2001-08-14 | 2017-04-04 | Tel Aviv University Future Technology Development L.P. | Glycosaminoglycan lipidated particles and their use in the supply of drugs and genes for diagnosis and therapy |
WO2003018018A2 (en) * | 2001-08-24 | 2003-03-06 | Neopharm, Inc. | Vinorelbine compositions and methods of use |
EP1939627B1 (en) | 2002-05-31 | 2010-08-18 | Cornell Research Foundation, Inc. | Methods to detect analytes in samples |
EP1530465B2 (en) | 2002-06-26 | 2015-12-16 | MediGene AG | Method of producing a cationic liposomal preparation comprising a lipophilic compound |
ES2686361T3 (en) * | 2002-10-29 | 2018-10-17 | Insmed Incorporated | Liposomes comprising an aminoglycoside for the treatment of lung infections |
US7879351B2 (en) | 2002-10-29 | 2011-02-01 | Transave, Inc. | High delivery rates for lipid based drug formulations, and methods of treatment thereof |
US7718189B2 (en) | 2002-10-29 | 2010-05-18 | Transave, Inc. | Sustained release of antiinfectives |
EP1565165A2 (en) * | 2002-11-26 | 2005-08-24 | Gilead Sciences, Inc. | Liposomal formulations |
US8980310B2 (en) * | 2002-12-31 | 2015-03-17 | Bharat Serums and Vaccines, Ltd. | Non-pegylated long-circulating liposomes |
ES2337563T3 (en) * | 2002-12-31 | 2010-04-27 | Zydus Bsv Pharma Private Limited | UNPEGLATED LIPOSOMES OF LASTING CIRCULATION. |
EP1596825A2 (en) * | 2003-02-03 | 2005-11-23 | Neopharm, Inc. | Stable sterile filterable liposomal encapsulated taxane and other antineoplastic drugs |
JP5107573B2 (en) * | 2003-04-25 | 2012-12-26 | ザ ペン ステイト リサーチ ファウンデーション | Systemic delivery methods and systems for growth-inhibiting lipid-derived bioactive compounds |
EP1668024A4 (en) * | 2003-09-29 | 2008-07-02 | Topigen Pharma Inc | Oligonucleotide compositions and methods for treating disease including inflammatory conditions |
EP1547582A1 (en) * | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Method of producing lipid complexed camptothecin-carboxylate |
AU2005251691A1 (en) * | 2004-05-17 | 2005-12-22 | Tekmira Pharmaceuticals Corporation | Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof |
US7749520B2 (en) * | 2004-07-07 | 2010-07-06 | Statens Serum Institut | Compositions and methods for stabilizing lipid based adjuvant formulations using glycolipids |
EP1809254A2 (en) * | 2004-10-28 | 2007-07-25 | Alza Corporation | Lyophilized liposome formulations and method |
CA2585972A1 (en) * | 2004-10-29 | 2006-05-11 | Neopharm, Inc. | Manufacturing process for liposomal preparations |
ES2450929T3 (en) * | 2004-10-29 | 2014-03-25 | Topigen Pharmaceuticals Inc. | Antisense oligonucleotides to treat allergy and proliferation of neoplastic cells |
US7195150B2 (en) * | 2004-12-20 | 2007-03-27 | Microsoft Corporation | Real time data from server |
US20080045575A1 (en) * | 2004-12-29 | 2008-02-21 | Van Dyke Thomas E | Delivery of H2 Antagonists |
EP1676569A1 (en) * | 2004-12-30 | 2006-07-05 | Pevion Biotech Ltd. | Lyophilization of virosomes |
US8221046B2 (en) | 2005-02-25 | 2012-07-17 | Johnson & Johnson Consumer Companies, Inc. | Compositions containing amines and use thereof |
AU2006228664B2 (en) | 2005-03-31 | 2012-11-01 | Julius-Maximilians-Universitat Wurzburg | Means for the inhibition of anti-beta1-adrenergic receptor antibodies |
AU2006242354B2 (en) * | 2005-04-29 | 2012-03-15 | University Of Louisville Research Foundation, Inc. | Cell-surface decoration with active agents |
CA2896083A1 (en) | 2005-12-08 | 2007-06-14 | Insmed Incorporated | Lipid-based compositions of antiinfectives for treating pulmonary infections and methods of use thereof |
US20140271782A1 (en) | 2013-03-15 | 2014-09-18 | Dermazone Solutions, Inc. | Method for preparing nanolipids with encapsulated alcohol |
EP3354260B1 (en) | 2006-04-06 | 2020-12-09 | Insmed Incorporated | Methods for coacervation induced liposomal encapsulation and formulations thereof |
JP2009537118A (en) * | 2006-05-19 | 2009-10-29 | トピジェン・ファーマシューティカルズ・インコーポレーテッド | Oligonucleotides affecting phosphodiesterase expression |
MX2008015337A (en) * | 2006-06-01 | 2009-11-26 | Inst Cardiologie Montreal | Method and compound for the treatment of valvular stenosis. |
US20100196455A1 (en) * | 2007-05-04 | 2010-08-05 | Transave, Inc. | Compositions of Multicationic Drugs for Reducing Interactions with Polyanionic Biomolecules and Methods of Use Thereof |
US9119783B2 (en) | 2007-05-07 | 2015-09-01 | Insmed Incorporated | Method of treating pulmonary disorders with liposomal amikacin formulations |
US9114081B2 (en) | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US9333214B2 (en) | 2007-05-07 | 2016-05-10 | Insmed Incorporated | Method for treating pulmonary disorders with liposomal amikacin formulations |
EP3127549B1 (en) | 2007-06-22 | 2019-12-18 | Children's Medical Center Corporation | Methods and uses thereof of a fragment of saposin a |
PL2197900T3 (en) | 2007-08-24 | 2012-12-31 | Univ Wuerzburg J Maximilians | Mutant double cyclized receptor peptides inhibiting beta 1-adrenoceptor antibodies |
US20090291132A1 (en) * | 2008-01-04 | 2009-11-26 | Brian Charles Keller | Enhanced delivery of antifungal agents |
US20120100067A1 (en) * | 2008-04-04 | 2012-04-26 | Medigene Ag | Solubilisation Method |
US20090281054A1 (en) * | 2008-05-06 | 2009-11-12 | Venkata Reddy | Compositions and methods comprising capuramycin analogues |
WO2009137912A1 (en) | 2008-05-15 | 2009-11-19 | Topigen Pharmaceuticals Inc. | Oligonucleotides for treating inflammation and neoplastic cell proliferation |
EP2123258A1 (en) | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes for drug delivery |
WO2010086337A1 (en) | 2009-01-27 | 2010-08-05 | Julius-Maximilians-Universität Würzburg | Novel peptide-homologues for inhibiting beta1-adrenoceptor antibodies |
AU2010213568B2 (en) | 2009-02-16 | 2014-11-20 | Cerenis Therapeutics Holding Sa | Apolipoprotein A-I Mimics |
US20100260830A1 (en) * | 2009-04-08 | 2010-10-14 | Brian A Salvatore | Liposomal Formulations of Tocopheryl Amides |
GB0913442D0 (en) | 2009-07-31 | 2009-09-16 | Univ Ramot | Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
US10143652B2 (en) | 2009-09-23 | 2018-12-04 | Curirx Inc. | Methods for the preparation of liposomes |
EP2480209A1 (en) * | 2009-09-23 | 2012-08-01 | Indu Javeri | Methods for the preparation of liposomes comprising docetaxel |
DK177529B1 (en) * | 2009-10-23 | 2013-09-08 | Bio Bedst Aps | Liposomes with improved storage stability |
EP2513137B1 (en) | 2009-12-17 | 2018-02-28 | Children's Medical Center Corporation | Saposin-a derived peptides and uses thereof |
WO2011123525A1 (en) * | 2010-04-01 | 2011-10-06 | The Regents Of The University Of California | Forming an artificial cell with controlled membrane composition, asymmetry and contents |
EP2394640A1 (en) | 2010-05-21 | 2011-12-14 | MediGene AG | Improved liposomal formulations of lipophilic compounds |
WO2011148207A1 (en) | 2010-05-28 | 2011-12-01 | Diagon Kft. | Procedure for biphasic preparation of liposomes and application thereof in manufacturing diagnostic reagents |
WO2011162818A2 (en) * | 2010-06-23 | 2011-12-29 | Controlled Nanovolumes, Inc. | Lecithin carrier vesicles and methods of making the same |
EP2646107A2 (en) | 2010-12-01 | 2013-10-09 | Spinal Modulation Inc. | Agent delivery systems for selective neuromodulation |
CN103153285B (en) * | 2010-12-27 | 2016-10-12 | 泰尔茂株式会社 | Liposome composition and manufacture method thereof |
JP6081995B2 (en) | 2011-06-17 | 2017-02-15 | プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ | Frizzled2 as a target for therapeutic antibodies in the treatment of cancer |
CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
SI2768484T1 (en) * | 2011-10-21 | 2019-12-31 | Jazz Pharmaceuticals Research Llc | Lyophilized liposomes |
ES2677895T3 (en) | 2011-12-22 | 2018-08-07 | Medizinische Universität Wien | Cyclotides as immunosuppressive agents |
EP3560509B1 (en) | 2011-12-22 | 2024-01-31 | Children's Medical Center Corporation | Saposin-a derived peptides and uses thereof |
US9737480B2 (en) | 2012-02-06 | 2017-08-22 | President And Fellows Of Harvard College | ARRDC1-mediated microvesicles (ARMMs) and uses thereof |
AU2013221292A1 (en) * | 2012-02-17 | 2014-09-11 | Celsion Corporation | Thermosensitive nanoparticle formulations and method of making the same |
US9849086B2 (en) | 2012-03-19 | 2017-12-26 | Nanologix Research, Inc. | Method and composition for treating cystitis |
AU2013202595B2 (en) | 2012-03-30 | 2016-04-21 | Biogen Ma Inc. | Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome |
JP6245481B2 (en) | 2012-04-17 | 2017-12-13 | メリマック ファーマシューティカルズ インコーポレーティッド | Compositions and methods for non-invasive imaging |
US9925143B2 (en) | 2012-04-18 | 2018-03-27 | Ramot At Tel-Aviv University Ltd. | Lipidated glycosaminoglycan particles for the delivery of nucleic acids |
CA2870860C (en) | 2012-05-21 | 2021-07-27 | Insmed Incorporated | Systems for treating pulmonary infections |
RU2675859C2 (en) | 2012-11-29 | 2018-12-25 | Инсмед Инкорпорейтед | Stabilised vancomycin formulations |
KR20150130430A (en) | 2013-03-14 | 2015-11-23 | 아이시스 파마수티컬즈 인코포레이티드 | Compositions and methods for modulating tau expression |
TWI657819B (en) | 2013-07-19 | 2019-05-01 | 美商Ionis製藥公司 | Compositions for modulating tau expression |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
US9737604B2 (en) | 2013-09-06 | 2017-08-22 | President And Fellows Of Harvard College | Use of cationic lipids to deliver CAS9 |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
ES2926985T3 (en) | 2014-05-15 | 2022-10-31 | Insmed Inc | Methods for treating nontuberculous mycobacterial lung infections |
US9392814B2 (en) | 2014-06-06 | 2016-07-19 | Nicholas J. Singer | Delivery system for drinks |
JP2017520549A (en) | 2014-06-26 | 2017-07-27 | ラモット アット テル アビブ ユニバーシティ, リミテッド | Liposome formulation for delivery of nucleic acids |
CA2956224A1 (en) | 2014-07-30 | 2016-02-11 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
TWI711629B (en) | 2014-09-03 | 2020-12-01 | 德商包林格因蓋爾漢國際股份有限公司 | Compound targeting il-23a and tnf-alpha and uses thereof |
US9816080B2 (en) | 2014-10-31 | 2017-11-14 | President And Fellows Of Harvard College | Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs) |
WO2016138287A1 (en) | 2015-02-25 | 2016-09-01 | Washington University | METHODS TO DETECT MOTOR NEURON DISEASE COMPRISING MICRO-RNAs |
KR20180016347A (en) * | 2015-04-13 | 2018-02-14 | 파운테인 테크놀로지스 인터내셔널, 엘엘씨 | Single-step method for the production of super-miniature lipid structures |
USD773313S1 (en) | 2015-06-23 | 2016-12-06 | Nicholas J. Singer | Package |
KR102644875B1 (en) | 2015-07-23 | 2024-03-06 | 베링거잉겔하임인터내쇼날유한회사 | Compounds targeting IL-23A and B-cell activating factor (BAFF) and uses thereof |
CN108513575A (en) | 2015-10-23 | 2018-09-07 | 哈佛大学的校长及成员们 | Nucleobase editing machine and application thereof |
US10435682B2 (en) | 2016-02-19 | 2019-10-08 | University Of South Florida | Arginine deiminase gene therapy for disordered proteins |
SG10201912099TA (en) | 2016-06-08 | 2020-02-27 | Childrens Medical Center | Engineered botulinum neurotoxins |
JP7158371B2 (en) | 2016-07-08 | 2022-10-21 | ザ チルドレンズ メディカル センター コーポレーション | Novel botulinum neurotoxin and its derivatives |
WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
JOP20190065A1 (en) | 2016-09-29 | 2019-03-28 | Ionis Pharmaceuticals Inc | Compounds and methods for reducing tau expression |
WO2018067546A1 (en) | 2016-10-03 | 2018-04-12 | President And Fellows Of Harvard College | Delivery of therapeutic rnas via arrdc1-mediated microvesicles |
KR102622411B1 (en) | 2016-10-14 | 2024-01-10 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | AAV delivery of nucleobase editor |
WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
CN110352242A (en) | 2016-12-23 | 2019-10-18 | 哈佛大学的校长及成员们 | The gene editing of PCSK9 |
AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
CN110662556A (en) | 2017-03-09 | 2020-01-07 | 哈佛大学的校长及成员们 | Cancer vaccine |
EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
WO2018176009A1 (en) | 2017-03-23 | 2018-09-27 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable dna binding proteins |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
CN111801345A (en) | 2017-07-28 | 2020-10-20 | 哈佛大学的校长及成员们 | Methods and compositions using an evolved base editor for Phage Assisted Continuous Evolution (PACE) |
WO2019139645A2 (en) | 2017-08-30 | 2019-07-18 | President And Fellows Of Harvard College | High efficiency base editors comprising gam |
JP2021500871A (en) | 2017-09-29 | 2021-01-14 | ザ チルドレンズ メディカル センター コーポレーション | Neurotoxin-like toxins and their use |
WO2019079347A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
US10538553B2 (en) | 2018-01-05 | 2020-01-21 | University Of South Florida | Compounds for the treatment of neurodegenerative diseases |
WO2019168953A1 (en) | 2018-02-27 | 2019-09-06 | President And Fellows Of Harvard College | Evolved cas9 variants and uses thereof |
WO2019191627A1 (en) | 2018-03-30 | 2019-10-03 | Insmed Incorporated | Methods for continuous manufacture of liposomal drug products |
US10507226B1 (en) | 2018-05-02 | 2019-12-17 | University Of South Florida | N-amino peptide beta-sheet mimics for the treatment of Alzheimer's disease |
EP3797160A1 (en) | 2018-05-23 | 2021-03-31 | The Broad Institute Inc. | Base editors and uses thereof |
WO2020051360A1 (en) | 2018-09-05 | 2020-03-12 | The Broad Institute, Inc. | Base editing for treating hutchinson-gilford progeria syndrome |
WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
WO2020102659A1 (en) | 2018-11-15 | 2020-05-22 | The Broad Institute, Inc. | G-to-t base editors and uses thereof |
WO2020181202A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to t:a base editing through adenine deamination and oxidation |
WO2020181195A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through adenine excision |
WO2020181180A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | A:t to c:g base editors and uses thereof |
WO2020181178A1 (en) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | T:a to a:t base editing through thymine alkylation |
US20220170013A1 (en) | 2019-03-06 | 2022-06-02 | The Broad Institute, Inc. | T:a to a:t base editing through adenosine methylation |
AU2020240109A1 (en) | 2019-03-19 | 2021-09-30 | President And Fellows Of Harvard College | Methods and compositions for editing nucleotide sequences |
WO2020210751A1 (en) | 2019-04-12 | 2020-10-15 | The Broad Institute, Inc. | System for genome editing |
WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
EP3973054A1 (en) | 2019-05-20 | 2022-03-30 | The Broad Institute Inc. | Aav delivery of nucleobase editors |
US20220315906A1 (en) | 2019-08-08 | 2022-10-06 | The Broad Institute, Inc. | Base editors with diversified targeting scope |
WO2021030666A1 (en) | 2019-08-15 | 2021-02-18 | The Broad Institute, Inc. | Base editing by transglycosylation |
WO2021050512A1 (en) | 2019-09-09 | 2021-03-18 | Beam Therapeutics Inc. | Novel crispr enzymes, methods, systems and uses thereof |
WO2021072328A1 (en) | 2019-10-10 | 2021-04-15 | The Broad Institute, Inc. | Methods and compositions for prime editing rna |
WO2021108717A2 (en) | 2019-11-26 | 2021-06-03 | The Broad Institute, Inc | Systems and methods for evaluating cas9-independent off-target editing of nucleic acids |
WO2021113494A1 (en) | 2019-12-03 | 2021-06-10 | Beam Therapeutics Inc. | Synthetic guide rna, compositions, methods, and uses thereof |
CA3166153A1 (en) | 2020-01-28 | 2021-08-05 | The Broad Institute, Inc. | Base editors, compositions, and methods for modifying the mitochondrial genome |
EP4100032A1 (en) | 2020-02-05 | 2022-12-14 | The Broad Institute Inc. | Gene editing methods for treating spinal muscular atrophy |
US20230235309A1 (en) | 2020-02-05 | 2023-07-27 | The Broad Institute, Inc. | Adenine base editors and uses thereof |
CA3168293A1 (en) | 2020-03-20 | 2021-09-23 | Christian Gruber | Cyclotides in combination with kappa opioid receptor ligands for ms therapy |
EP4143315A1 (en) | 2020-04-28 | 2023-03-08 | The Broad Institute Inc. | <smallcaps/>? ? ?ush2a? ? ? ? ?targeted base editing of thegene |
AU2021267940A1 (en) | 2020-05-08 | 2022-12-08 | President And Fellows Of Harvard College | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
EP4237556A2 (en) | 2020-10-28 | 2023-09-06 | Children's Medical Center Corporation | Truncated modified recombinant adamts13 and uses thereof |
JP2024507533A (en) | 2021-02-19 | 2024-02-20 | ビーム・セラピューティクス・インコーポレイテッド | Recombinant rabies virus for gene therapy |
KR20230158531A (en) | 2021-03-23 | 2023-11-20 | 빔 테라퓨틱스, 인크. | Novel CRISPR enzymes, methods, systems and uses thereof |
AU2022256513A1 (en) | 2021-04-16 | 2023-11-02 | Beam Therapeutics Inc. | Genetic modification of hepatocytes |
WO2022261509A1 (en) | 2021-06-11 | 2022-12-15 | The Broad Institute, Inc. | Improved cytosine to guanine base editors |
CA3226664A1 (en) | 2021-07-23 | 2023-01-26 | Brian CAFFERTY | Guide rnas for crispr/cas editing systems |
CA3230629A1 (en) | 2021-09-08 | 2023-03-16 | Beam Therapeutics Inc. | Viral guide rna delivery |
WO2023076898A1 (en) | 2021-10-25 | 2023-05-04 | The Broad Institute, Inc. | Methods and compositions for editing a genome with prime editing and a recombinase |
WO2023081756A1 (en) | 2021-11-03 | 2023-05-11 | The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone | Precise genome editing using retrons |
WO2023094435A1 (en) | 2021-11-23 | 2023-06-01 | Cellectis Sa | New tale protein scaffolds with improved on-target/off-target activity ratios |
WO2023102538A1 (en) | 2021-12-03 | 2023-06-08 | The Broad Institute, Inc. | Self-assembling virus-like particles for delivery of prime editors and methods of making and using same |
WO2023102537A2 (en) | 2021-12-03 | 2023-06-08 | The Broad Institute, Inc. | Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same |
WO2023114953A2 (en) | 2021-12-17 | 2023-06-22 | Beam Therapeutics Inc. | Novel crispr enzymes, methods, systems and uses thereof |
WO2023196802A1 (en) | 2022-04-04 | 2023-10-12 | The Broad Institute, Inc. | Cas9 variants having non-canonical pam specificities and uses thereof |
WO2023196772A1 (en) | 2022-04-04 | 2023-10-12 | Beam Therapeutics Inc. | Novel rna base editing compositions, systems, methods and uses thereof |
WO2023205687A1 (en) | 2022-04-20 | 2023-10-26 | The Broad Institute, Inc. | Improved prime editing methods and compositions |
WO2023212715A1 (en) | 2022-04-28 | 2023-11-02 | The Broad Institute, Inc. | Aav vectors encoding base editors and uses thereof |
WO2023230613A1 (en) | 2022-05-27 | 2023-11-30 | The Broad Institute, Inc. | Improved mitochondrial base editors and methods for editing mitochondrial dna |
WO2023240137A1 (en) | 2022-06-08 | 2023-12-14 | The Board Institute, Inc. | Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing |
WO2024040083A1 (en) | 2022-08-16 | 2024-02-22 | The Broad Institute, Inc. | Evolved cytosine deaminases and methods of editing dna using same |
WO2024059791A1 (en) | 2022-09-16 | 2024-03-21 | Beam Therapeutics Inc. | Large serine recombinases, systems and uses thereof |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NO132132C (en) * | 1968-10-10 | 1975-09-24 | David George Marsh | |
US3541201A (en) * | 1968-12-18 | 1970-11-17 | Ethan Alan Brown | Novel sodium chloride encapsulated injectionable substances |
US3903067A (en) * | 1969-08-06 | 1975-09-02 | Beecham Group Ltd | Allergenic extracts reacted with epihalohydrins |
GB1282163A (en) * | 1969-08-06 | 1972-07-19 | Beecham Group Ltd | Modified allergens and a process for their preparation |
US3893993A (en) * | 1969-08-06 | 1975-07-08 | Beecham Group Ltd | Allergenic extracts cross linked under acid conditions with inorganic cyanates |
US3825525A (en) * | 1969-08-06 | 1974-07-23 | Beecham Group Ltd | Allergens reacted with carbodiimides |
US3773919A (en) * | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US3761585A (en) * | 1971-04-05 | 1973-09-25 | Beecham Group Ltd | Vaccines containing modified allergenic material |
GB1377074A (en) * | 1971-07-13 | 1974-12-11 | Beecham Group Ltd | Process for preparing injectable compositions |
CH594444A5 (en) * | 1972-12-04 | 1978-01-13 | Gerd Birrenbach | |
US4180562A (en) * | 1973-05-08 | 1979-12-25 | Northwestern University | Glutaraldehyde polymerized ragweed antigen E preparation for treatment of allergic patients sensitive to ragweed pollen |
US4351337A (en) * | 1973-05-17 | 1982-09-28 | Arthur D. Little, Inc. | Biodegradable, implantable drug delivery device, and process for preparing and using the same |
US3962429A (en) * | 1973-08-01 | 1976-06-08 | Chugai Seiyaku Kabushiki Kaisha | Method for reducing side effects of aminoglycoside antibiotics and composition therefor |
US3976071A (en) * | 1974-01-07 | 1976-08-24 | Dynatech Corporation | Methods of improving control of release rates and products useful in same |
US4070455A (en) * | 1974-02-16 | 1978-01-24 | Beecham Group Limited | Process for preparing injectable desensitizing compositions and products thereof in microparticle form |
GB1502774A (en) * | 1974-06-25 | 1978-03-01 | Nat Res Dev | Immunological preparations |
US3978203A (en) * | 1974-07-12 | 1976-08-31 | Dynatech Corporation | Sustained release of pharmaceuticals from polyester matrices |
JPS5186117A (en) * | 1975-01-27 | 1976-07-28 | Tanabe Seiyaku Co | Johoseibiryushiseizainoseiho |
US4131648A (en) * | 1975-01-28 | 1978-12-26 | Alza Corporation | Structured orthoester and orthocarbonate drug delivery devices |
US4093709A (en) * | 1975-01-28 | 1978-06-06 | Alza Corporation | Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates) |
US4217344A (en) * | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
GB1578348A (en) * | 1976-08-17 | 1980-11-05 | Pharmacia Ab | Products and a method for the therapeutic suppression of reaginic antibodies responsible for common allergic |
US4140679A (en) * | 1976-10-12 | 1979-02-20 | Research Corporation | Antigen-protein complex for blocking allergic reactions |
US4391797A (en) * | 1977-01-05 | 1983-07-05 | The Children's Hospital Medical Center | Systems for the controlled release of macromolecules |
US4164560A (en) * | 1977-01-05 | 1979-08-14 | Folkman Moses J | Systems for the controlled release of macromolecules |
GB1575343A (en) * | 1977-05-10 | 1980-09-17 | Ici Ltd | Method for preparing liposome compositions containing biologically active compounds |
CH621479A5 (en) * | 1977-08-05 | 1981-02-13 | Battelle Memorial Institute | |
US4460577A (en) * | 1977-09-30 | 1984-07-17 | Farmitalia Carlo Erba S.P.A. | Pharmaceutical compositions consisting or consisting essentially of liposomes, and processes for making same |
FR2416008A1 (en) * | 1978-02-02 | 1979-08-31 | Oreal | LIPOSOME LYOPHILISATES |
US4235871A (en) * | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4193983A (en) * | 1978-05-16 | 1980-03-18 | Syva Company | Labeled liposome particle compositions and immunoassays therewith |
US4489055A (en) * | 1978-07-19 | 1984-12-18 | N.V. Sopar S.A. | Process for preparing biodegradable submicroscopic particles containing a biologically active substance and their use |
US4329332A (en) * | 1978-07-19 | 1982-05-11 | Patrick Couvreur | Biodegradable submicroscopic particles containing a biologically active substance and compositions containing them |
US4215036A (en) * | 1978-08-15 | 1980-07-29 | Research Corporation | Modified grass pollen antigens |
US4256732A (en) * | 1978-08-15 | 1981-03-17 | Research Corporation | Modified grass pollen antigens |
US4222907A (en) * | 1978-09-25 | 1980-09-16 | Scripps Clinic & Research Foundation | Induction of immunological tolerance |
US4234569A (en) * | 1978-10-04 | 1980-11-18 | The Johns Hopkins University | Production of aldehyde-treated allergen-containing substances |
US4241046A (en) * | 1978-11-30 | 1980-12-23 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4276206A (en) * | 1979-01-18 | 1981-06-30 | Scripps Clinic & Research Foundation | Immunochemical conjugates: method and composition |
US4220565A (en) * | 1979-01-18 | 1980-09-02 | Scripps Clinic & Research Foundation | Immunochemical conjugates: method and composition |
CA1173360A (en) * | 1979-06-22 | 1984-08-28 | Jurg Schrank | Pharmaceutical preparations |
US4269764A (en) * | 1979-08-02 | 1981-05-26 | Roy Patterson | Preparation for treatment of allergic patients sensitive to ragweed pollen |
US4293539A (en) * | 1979-09-12 | 1981-10-06 | Eli Lilly And Company | Controlled release formulations and method of treatment |
ATE8584T1 (en) * | 1980-01-16 | 1984-08-15 | Hans Georg Prof. Dr. Weder | METHOD AND DIALYZER EQUIPMENT FOR THE MANUFACTURE OF BILAYER VESICLES AND USE OF THE BILAYER VESICLES. |
US4253996A (en) * | 1980-02-13 | 1981-03-03 | Scripps Clinic And Research Foundation | Immunochemical conjugates: method and composition |
US4338297A (en) * | 1980-02-19 | 1982-07-06 | Michael Jacob G | Polypeptide active pollen immunosuppressant fraction |
US4469677A (en) * | 1980-02-19 | 1984-09-04 | Michael J Gabriel | Polypeptide active immunosuppressant fraction |
US4439199A (en) * | 1980-02-19 | 1984-03-27 | Alza Corporation | Method for administering immunopotentiator |
DE3160926D1 (en) * | 1980-04-15 | 1983-10-27 | Beecham Group Plc | Allergens modified with polysarcosines |
JPS574913A (en) * | 1980-06-11 | 1982-01-11 | Green Cross Corp:The | Urokinase preparation for oral administration |
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
JPS5782310A (en) * | 1980-11-11 | 1982-05-22 | Tanabe Seiyaku Co Ltd | Production of liposome preparation |
JPS5782311A (en) * | 1980-11-11 | 1982-05-22 | Tanabe Seiyaku Co Ltd | Production of liposome preparation |
US4675189A (en) * | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
IE52535B1 (en) * | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
EP0064366A1 (en) * | 1981-04-29 | 1982-11-10 | Beecham Group Plc | Pharmaceutical compositions |
US4397846A (en) * | 1981-05-15 | 1983-08-09 | Murray Weiner | Storage-stable lipid vesicles and method of preparation |
US4485045A (en) * | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4713249A (en) * | 1981-11-12 | 1987-12-15 | Schroeder Ulf | Crystallized carbohydrate matrix for biologically active substances, a process of preparing said matrix, and the use thereof |
US4522803A (en) * | 1983-02-04 | 1985-06-11 | The Liposome Company, Inc. | Stable plurilamellar vesicles, their preparation and use |
DE3378250D1 (en) * | 1982-04-22 | 1988-11-24 | Ici Plc | Continuous release formulations |
JPS58201711A (en) * | 1982-05-19 | 1983-11-24 | Eisai Co Ltd | Coated liposome containing ubidecarenone |
US4489056A (en) * | 1982-06-30 | 1984-12-18 | Merck & Co., Inc. | Acid anhydrides as rate controlling agent for the erosion of polymers which latter polymers have beneficial substances dispersed throughout their matrix or where the polymer matrix surrounds the beneficial substance |
US4485054A (en) * | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
JPS5964691A (en) * | 1982-10-05 | 1984-04-12 | Nippon Kokan Kk <Nkk> | Device and method for drilling hole in brick at the tope of coke oven |
JPS5976021A (en) * | 1982-10-22 | 1984-04-28 | Fujisawa Pharmaceut Co Ltd | Liposome pharmaceutical containing substance fk-565 |
GB2134869A (en) * | 1983-02-15 | 1984-08-22 | Squibb & Sons Inc | Method of preparing liposomes and products produced thereby |
US4757128A (en) * | 1986-08-01 | 1988-07-12 | Massachusetts Institute Of Technology | High molecular weight polyanhydride and preparation thereof |
US4588578A (en) * | 1983-08-08 | 1986-05-13 | The Liposome Company, Inc. | Lipid vesicles prepared in a monophase |
US4515736A (en) * | 1983-05-12 | 1985-05-07 | The Regents Of The University Of California | Method for encapsulating materials into liposomes |
EP0150184A1 (en) * | 1983-07-01 | 1985-08-07 | Battelle Memorial Institute | Biodegradable polypeptide and utilization thereof for the progressive release of drugs |
CA1256638A (en) * | 1984-07-06 | 1989-06-27 | Motoaki Tanaka | Polymer and its production |
US4629621A (en) * | 1984-07-23 | 1986-12-16 | Zetachron, Inc. | Erodible matrix for sustained release bioactive composition |
SE8403905D0 (en) * | 1984-07-30 | 1984-07-30 | Draco Ab | LIPOSOMES AND STEROID ESTERS |
US4880635B1 (en) * | 1984-08-08 | 1996-07-02 | Liposome Company | Dehydrated liposomes |
US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
US4638045A (en) * | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
US4885172A (en) * | 1985-06-26 | 1989-12-05 | The Liposome Company, Inc. | Composition for targeting, storing and loading of liposomes |
US4683092A (en) * | 1985-07-03 | 1987-07-28 | Damon Biotech, Inc. | Capsule loading technique |
US4713244A (en) * | 1985-08-16 | 1987-12-15 | Bausch & Lomb Incorporated | Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent |
US4806343A (en) * | 1986-03-13 | 1989-02-21 | University Of Southwestern Louisiana | Cryogenic protectant for proteins |
US4741872A (en) * | 1986-05-16 | 1988-05-03 | The University Of Kentucky Research Foundation | Preparation of biodegradable microspheres useful as carriers for macromolecules |
US5667452A (en) * | 1995-04-06 | 1997-09-16 | Caterpillar Inc. | Split torque transmission |
-
1985
- 1985-07-26 US US06759419 patent/US4880635B1/en not_active Expired - Lifetime
- 1985-08-02 CA CA000488004A patent/CA1270197A/en not_active Expired - Lifetime
- 1985-08-04 IL IL76010A patent/IL76010A/en not_active IP Right Cessation
- 1985-08-07 EP EP85904187A patent/EP0190315B2/en not_active Expired - Lifetime
- 1985-08-07 DE DE3588148T patent/DE3588148T2/en not_active Expired - Lifetime
- 1985-08-07 EP EP93105130A patent/EP0562641B1/en not_active Expired - Lifetime
- 1985-08-07 PT PT80926A patent/PT80926B/en unknown
- 1985-08-07 ES ES545955A patent/ES8701516A1/en not_active Expired
- 1985-08-07 DE DE3587639T patent/DE3587639T3/en not_active Expired - Lifetime
- 1985-08-07 JP JP60503630A patent/JPH0818973B2/en not_active Expired - Lifetime
- 1985-08-07 DE DE3588146T patent/DE3588146T2/en not_active Expired - Lifetime
- 1985-08-07 EP EP93105132A patent/EP0561424B1/en not_active Expired - Lifetime
- 1985-08-07 WO PCT/US1985/001502 patent/WO1986001103A1/en active IP Right Grant
- 1985-08-07 AT AT93105130T patent/ATE149347T1/en not_active IP Right Cessation
- 1985-08-07 AT AT93105132T patent/ATE149346T1/en not_active IP Right Cessation
- 1985-08-08 IE IE196585A patent/IE68686B1/en not_active IP Right Cessation
-
1986
- 1986-02-17 ES ES552076A patent/ES8704755A1/en not_active Expired
-
1990
- 1990-03-23 CA CA000615683A patent/CA1283604C/en not_active Expired - Lifetime
- 1990-03-23 CA CA000615684A patent/CA1294548C/en not_active Expired - Lifetime
-
1993
- 1993-02-24 US US08/022,819 patent/US5578320A/en not_active Expired - Lifetime
-
1994
- 1994-08-22 JP JP6196981A patent/JP2579441B2/en not_active Expired - Lifetime
- 1994-08-22 JP JP6196982A patent/JP2579442B2/en not_active Expired - Lifetime
-
1995
- 1995-05-25 US US08/450,831 patent/US5837279A/en not_active Expired - Lifetime
-
1997
- 1997-06-16 US US08/876,938 patent/US5922350A/en not_active Expired - Lifetime
-
1998
- 1998-06-25 HK HK98106752A patent/HK1007501A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1283604C (en) | Dehydrated liposomes | |
JP2572553B2 (en) | Method for loading drug into liposome | |
US6447800B2 (en) | Method of loading preformed liposomes using ethanol | |
Madden et al. | Protection of large unilamellar vesicles by trehalose during dehydration: retention of vesicle contents | |
US5077056A (en) | Encapsulation of antineoplastic agents in liposomes | |
US5736155A (en) | Encapsulation of antineoplastic agents in liposomes | |
US5169637A (en) | Stable plurilamellar vesicles | |
EP0231261B1 (en) | Multilamellar liposomes having improved trapping efficiencies | |
Webb et al. | The cationic lipid stearylamine reduces the permeability of the cationic drugs verapamil and prochlorperazine to lipid bilayers: implications for drug delivery | |
Al-Angary et al. | Characterization, stability and in vivo targeting of liposomal formulations containing cyclosporin | |
Montero et al. | The active trapping of doxorubicin in liposomes by pH gradient: photon correlation spectroscopy and fluorimetric study | |
Gürsoy et al. | Stability of indomethacin-containing liposomes on long-term storage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry | ||
MKEX | Expiry |
Effective date: 20080430 |